WO2008087366A2 - Derives de 3-phenyl-1-(phenylthienyl)propan-1-one et de 3-phenyl-1-(phenylfuranyl)propan-1-one substitues, preparation et utilisation - Google Patents
Derives de 3-phenyl-1-(phenylthienyl)propan-1-one et de 3-phenyl-1-(phenylfuranyl)propan-1-one substitues, preparation et utilisation Download PDFInfo
- Publication number
- WO2008087366A2 WO2008087366A2 PCT/FR2007/052634 FR2007052634W WO2008087366A2 WO 2008087366 A2 WO2008087366 A2 WO 2008087366A2 FR 2007052634 W FR2007052634 W FR 2007052634W WO 2008087366 A2 WO2008087366 A2 WO 2008087366A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- thien
- propyl
- phenoxy
- trifluoromethyl
- Prior art date
Links
- MGEHRPYCKYAMOO-UHFFFAOYSA-N 3-phenyl-1-(3-phenylthiophen-2-yl)propan-1-one Chemical class S1C=CC(C=2C=CC=CC=2)=C1C(=O)CCC1=CC=CC=C1 MGEHRPYCKYAMOO-UHFFFAOYSA-N 0.000 title claims description 6
- LHOQHROLANFZAT-UHFFFAOYSA-N 3-phenyl-1-(3-phenylfuran-2-yl)propan-1-one Chemical class O1C=CC(C=2C=CC=CC=2)=C1C(=O)CCC1=CC=CC=C1 LHOQHROLANFZAT-UHFFFAOYSA-N 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title description 4
- -1 3-phenyl-1-(thien-2- yl)propan-1-one derivative compounds Chemical class 0.000 claims abstract description 111
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 320
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 173
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 167
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 130
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 118
- 238000011282 treatment Methods 0.000 claims description 117
- 125000000217 alkyl group Chemical group 0.000 claims description 67
- 125000004432 carbon atom Chemical group C* 0.000 claims description 51
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 48
- 150000002632 lipids Chemical class 0.000 claims description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 35
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical group 0.000 claims description 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 23
- 230000037356 lipid metabolism Effects 0.000 claims description 22
- 230000007170 pathology Effects 0.000 claims description 21
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 20
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 230000023852 carbohydrate metabolic process Effects 0.000 claims description 17
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 206010012601 diabetes mellitus Diseases 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 14
- 208000008589 Obesity Diseases 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 13
- 229940125396 insulin Drugs 0.000 claims description 13
- 235000020824 obesity Nutrition 0.000 claims description 13
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 206010022489 Insulin Resistance Diseases 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 9
- 201000001320 Atherosclerosis Diseases 0.000 claims description 9
- 102000004877 Insulin Human genes 0.000 claims description 9
- 108090001061 Insulin Proteins 0.000 claims description 9
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 8
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 8
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 239000011593 sulfur Substances 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 150000003839 salts Chemical group 0.000 claims description 7
- 239000007787 solid Chemical group 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 230000003178 anti-diabetic effect Effects 0.000 claims description 6
- 230000000055 hyoplipidemic effect Effects 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- KGKFHXDRDIHYGO-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-[5-(4-methylsulfanylphenyl)thiophen-2-yl]-3-oxopropyl]phenoxy]-2-methylpropanoic acid Chemical compound C1=CC(SC)=CC=C1C1=CC=C(C(=O)CCC=2C(=C(Cl)C(OC(C)(C)C(O)=O)=CC=2)Cl)S1 KGKFHXDRDIHYGO-UHFFFAOYSA-N 0.000 claims description 5
- ZLFJYBKUOOAXGR-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-oxo-3-(5-phenylthiophen-2-yl)propyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC=CC=2)S1 ZLFJYBKUOOAXGR-UHFFFAOYSA-N 0.000 claims description 5
- RMNSNZMBRZRLMM-UHFFFAOYSA-N 2-[2,6-dimethyl-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2SC(=CC=2)C=2C=CC(=CC=2)C(F)(F)F)=C1 RMNSNZMBRZRLMM-UHFFFAOYSA-N 0.000 claims description 5
- AGVGXYDUEZTMIX-UHFFFAOYSA-N 2-[2-fluoro-4-[3-phenylmethoxy-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]butanoic acid Chemical compound C1=C(F)C(OC(CC)C(O)=O)=CC=C1CCC(C=1SC(=CC=1)C=1C=CC(=CC=1)C(F)(F)F)OCC1=CC=CC=C1 AGVGXYDUEZTMIX-UHFFFAOYSA-N 0.000 claims description 5
- MBYLQRMRALFFPQ-UHFFFAOYSA-N 2-[4-[3-[5-(4-bromophenyl)thiophen-2-yl]-3-oxopropyl]-2,3-dichlorophenoxy]-2-methylpropanoic acid Chemical compound ClC1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(Br)=CC=2)S1 MBYLQRMRALFFPQ-UHFFFAOYSA-N 0.000 claims description 5
- 201000006474 Brain Ischemia Diseases 0.000 claims description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 206010008118 cerebral infarction Diseases 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- XSVAKYOALRYMGZ-UHFFFAOYSA-N ethyl 2-[2,3-dichloro-4-[3-oxo-3-[5-[3-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoate Chemical compound ClC1=C(Cl)C(OC(C)(C)C(=O)OCC)=CC=C1CCC(=O)C1=CC=C(C=2C=C(C=CC=2)C(F)(F)F)S1 XSVAKYOALRYMGZ-UHFFFAOYSA-N 0.000 claims description 5
- SSXNDNMVXPRQAY-UHFFFAOYSA-N ethyl 2-[2,3-dichloro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-phenylacetate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)OC(C(=C1Cl)Cl)=CC=C1CCC(=O)C(S1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 SSXNDNMVXPRQAY-UHFFFAOYSA-N 0.000 claims description 5
- 125000003544 oxime group Chemical group 0.000 claims description 5
- QMIUIJXEJBCBMW-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]furan-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)O1 QMIUIJXEJBCBMW-UHFFFAOYSA-N 0.000 claims description 4
- VKWFUXXYEOKEMO-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-phenylmethoxy-3-[4-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(C=1SC=C(C=1)C=1C=CC(=CC=1)C(F)(F)F)OCC1=CC=CC=C1 VKWFUXXYEOKEMO-UHFFFAOYSA-N 0.000 claims description 4
- DKQSCBCSVQAEJZ-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-propan-2-yloxy-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound C=1C=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1C(OC(C)C)CCC1=CC=C(OC(C)(C)C(O)=O)C(Cl)=C1Cl DKQSCBCSVQAEJZ-UHFFFAOYSA-N 0.000 claims description 4
- JQKYYNKAYICCSG-UHFFFAOYSA-N 2-[2,3-difluoro-4-[3-hydroxy-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound FC1=C(F)C(OC(C)(C)C(O)=O)=CC=C1CCC(O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 JQKYYNKAYICCSG-UHFFFAOYSA-N 0.000 claims description 4
- ZPOIBONXODOKNB-UHFFFAOYSA-N 2-[2,3-difluoro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound FC1=C(F)C(OC(C)(C)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 ZPOIBONXODOKNB-UHFFFAOYSA-N 0.000 claims description 4
- SCKAPQKOJSBTCD-UHFFFAOYSA-N 2-[2,3-difluoro-4-[3-phenylmethoxy-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound FC1=C(F)C(OC(C)(C)C(O)=O)=CC=C1CCC(C=1SC(=CC=1)C=1C=CC(=CC=1)C(F)(F)F)OCC1=CC=CC=C1 SCKAPQKOJSBTCD-UHFFFAOYSA-N 0.000 claims description 4
- PVIYWCHATVONDP-UHFFFAOYSA-N 2-[2-bromo-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound C1=C(Br)C(OC(C)(C)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 PVIYWCHATVONDP-UHFFFAOYSA-N 0.000 claims description 4
- QDWNDPDFPTYGHC-UHFFFAOYSA-N 2-[2-fluoro-4-[3-hydroxy-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]acetic acid Chemical compound C=1C=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1C(O)CCC1=CC=C(OCC(O)=O)C(F)=C1 QDWNDPDFPTYGHC-UHFFFAOYSA-N 0.000 claims description 4
- PLBRFVDPEZDDNU-UHFFFAOYSA-N 2-[2-fluoro-4-[3-hydroxy-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]butanoic acid Chemical compound C1=C(F)C(OC(CC)C(O)=O)=CC=C1CCC(O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 PLBRFVDPEZDDNU-UHFFFAOYSA-N 0.000 claims description 4
- JLKYUDDEOAGMDO-UHFFFAOYSA-N 2-[2-fluoro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]acetic acid Chemical compound C1=C(F)C(OCC(=O)O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 JLKYUDDEOAGMDO-UHFFFAOYSA-N 0.000 claims description 4
- IGMGSOFCHILBOS-UHFFFAOYSA-N 2-[2-fluoro-4-[3-phenylmethoxy-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]acetic acid Chemical compound C1=C(F)C(OCC(=O)O)=CC=C1CCC(C=1SC(=CC=1)C=1C=CC(=CC=1)C(F)(F)F)OCC1=CC=CC=C1 IGMGSOFCHILBOS-UHFFFAOYSA-N 0.000 claims description 4
- DEPCONCBRMXPBK-UHFFFAOYSA-N 2-[4-[3-hydroxy-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]-2,6-dimethylphenoxy]-2-methylpropanoic acid Chemical compound CC1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(O)C=2SC(=CC=2)C=2C=CC(=CC=2)C(F)(F)F)=C1 DEPCONCBRMXPBK-UHFFFAOYSA-N 0.000 claims description 4
- NSTJRGOVHVVPSP-UHFFFAOYSA-N 2-[4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]butanoic acid Chemical compound C1=CC(OC(CC)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 NSTJRGOVHVVPSP-UHFFFAOYSA-N 0.000 claims description 4
- MIGUUJLEWDCDNL-UHFFFAOYSA-N 2-methyl-2-[4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]propanoic acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 MIGUUJLEWDCDNL-UHFFFAOYSA-N 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 239000002220 antihypertensive agent Substances 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 4
- ZKKCTXOCFIZPPJ-UHFFFAOYSA-N ethyl 2-[2,3-dichloro-4-[3-methoxy-3-[5-[3-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoate Chemical compound ClC1=C(Cl)C(OC(C)(C)C(=O)OCC)=CC=C1CCC(OC)C1=CC=C(C=2C=C(C=CC=2)C(F)(F)F)S1 ZKKCTXOCFIZPPJ-UHFFFAOYSA-N 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- GRSTWPBYJBIVJZ-UHFFFAOYSA-N tert-butyl 2-[2,3-dichloro-4-[3-[5-(4-methylsulfanylphenyl)thiophen-2-yl]-3-oxopropyl]phenoxy]-2-methylpropanoate Chemical compound C1=CC(SC)=CC=C1C1=CC=C(C(=O)CCC=2C(=C(Cl)C(OC(C)(C)C(=O)OC(C)(C)C)=CC=2)Cl)S1 GRSTWPBYJBIVJZ-UHFFFAOYSA-N 0.000 claims description 4
- FSMIYXNKENWFRF-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-(pyridin-3-ylmethoxy)-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(C=1SC(=CC=1)C=1C=CC(=CC=1)C(F)(F)F)OCC1=CC=CN=C1 FSMIYXNKENWFRF-UHFFFAOYSA-N 0.000 claims description 3
- UZULRYBSISHQGM-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-ethoxy-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound C=1C=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1C(OCC)CCC1=CC=C(OC(C)(C)C(O)=O)C(Cl)=C1Cl UZULRYBSISHQGM-UHFFFAOYSA-N 0.000 claims description 3
- OHQFLGUNWUFKDI-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-hydroxy-3-[5-[4-(trifluoromethyl)phenyl]furan-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)O1 OHQFLGUNWUFKDI-UHFFFAOYSA-N 0.000 claims description 3
- HOZGBVINKMKSEA-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-methoxy-3-[5-[4-(trifluoromethyl)phenyl]furan-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound C=1C=C(C=2C=CC(=CC=2)C(F)(F)F)OC=1C(OC)CCC1=CC=C(OC(C)(C)C(O)=O)C(Cl)=C1Cl HOZGBVINKMKSEA-UHFFFAOYSA-N 0.000 claims description 3
- KBMLCYSJSGLZQC-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-oxo-3-[4-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(=O)C1=CC(C=2C=CC(=CC=2)C(F)(F)F)=CS1 KBMLCYSJSGLZQC-UHFFFAOYSA-N 0.000 claims description 3
- ZBCOMVJFUHVFBW-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-oxo-3-[5-[3-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C=2C=C(C=CC=2)C(F)(F)F)S1 ZBCOMVJFUHVFBW-UHFFFAOYSA-N 0.000 claims description 3
- IYAMNNKIQHBFLW-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-phenylmethoxy-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(C=1SC(=CC=1)C=1C=CC(=CC=1)C(F)(F)F)OCC1=CC=CC=C1 IYAMNNKIQHBFLW-UHFFFAOYSA-N 0.000 claims description 3
- KPPGKEFZXWDFOI-UHFFFAOYSA-N 2-[2-bromo-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]acetic acid Chemical compound C1=C(Br)C(OCC(=O)O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 KPPGKEFZXWDFOI-UHFFFAOYSA-N 0.000 claims description 3
- JAEYRLHBLUOPMT-UHFFFAOYSA-N 2-[2-chloro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound C1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 JAEYRLHBLUOPMT-UHFFFAOYSA-N 0.000 claims description 3
- JCDBUKZZHPIWOY-UHFFFAOYSA-N 2-[2-fluoro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound C1=C(F)C(OC(C)(C)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 JCDBUKZZHPIWOY-UHFFFAOYSA-N 0.000 claims description 3
- IPFWHSKUDDTXDX-UHFFFAOYSA-N 2-[2-fluoro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]butanoic acid Chemical compound C1=C(F)C(OC(CC)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 IPFWHSKUDDTXDX-UHFFFAOYSA-N 0.000 claims description 3
- PSPYWPAJNSDSPQ-UHFFFAOYSA-N 2-[4-[3-methoxy-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]-2,6-dimethylphenoxy]-2-methylpropanoic acid Chemical compound C=1C=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1C(OC)CCC1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 PSPYWPAJNSDSPQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000002009 alkene group Chemical group 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 239000003472 antidiabetic agent Substances 0.000 claims description 3
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 150000004677 hydrates Chemical group 0.000 claims description 3
- 125000006480 iodobenzyl group Chemical group 0.000 claims description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- QQUBFLODBGTLGZ-UHFFFAOYSA-N tert-butyl 2-[2,3-dichloro-4-[3-oxo-3-(5-phenylthiophen-2-yl)propyl]phenoxy]-2-methylpropanoate Chemical compound ClC1=C(Cl)C(OC(C)(C)C(=O)OC(C)(C)C)=CC=C1CCC(=O)C1=CC=C(C=2C=CC=CC=2)S1 QQUBFLODBGTLGZ-UHFFFAOYSA-N 0.000 claims description 3
- YREZFWKAZGIRDN-UHFFFAOYSA-N tert-butyl 2-[2,3-dichloro-4-[3-oxo-3-[5-[4-(trifluoromethoxy)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoate Chemical compound ClC1=C(Cl)C(OC(C)(C)C(=O)OC(C)(C)C)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(OC(F)(F)F)=CC=2)S1 YREZFWKAZGIRDN-UHFFFAOYSA-N 0.000 claims description 3
- IFOBNSRQHOHOQA-UHFFFAOYSA-N tert-butyl 2-[2,6-dimethyl-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoate Chemical compound CC1=C(OC(C)(C)C(=O)OC(C)(C)C)C(C)=CC(CCC(=O)C=2SC(=CC=2)C=2C=CC(=CC=2)C(F)(F)F)=C1 IFOBNSRQHOHOQA-UHFFFAOYSA-N 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 229940124549 vasodilator Drugs 0.000 claims description 3
- 239000003071 vasodilator agent Substances 0.000 claims description 3
- GCHBFENMZLIJIW-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-hydroxy-3-[4-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(O)C1=CC(C=2C=CC(=CC=2)C(F)(F)F)=CS1 GCHBFENMZLIJIW-UHFFFAOYSA-N 0.000 claims description 2
- RGLBRVOZSQLZHE-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-hydroxy-3-[5-[4-(trifluoromethoxy)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(O)C1=CC=C(C=2C=CC(OC(F)(F)F)=CC=2)S1 RGLBRVOZSQLZHE-UHFFFAOYSA-N 0.000 claims description 2
- IFSLEUVJORAOFJ-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-hydroxyimino-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(=NO)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 IFSLEUVJORAOFJ-UHFFFAOYSA-N 0.000 claims description 2
- SROVOYHVTDTJHF-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-methoxy-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound C=1C=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1C(OC)CCC1=CC=C(OC(C)(C)C(O)=O)C(Cl)=C1Cl SROVOYHVTDTJHF-UHFFFAOYSA-N 0.000 claims description 2
- MZAHSTXCPULVPW-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-phenylacetic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)OC(C(=C1Cl)Cl)=CC=C1CCC(=O)C(S1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 MZAHSTXCPULVPW-UHFFFAOYSA-N 0.000 claims description 2
- ZKQXHEGZRVWJID-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]acetic acid Chemical compound ClC1=C(Cl)C(OCC(=O)O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 ZKQXHEGZRVWJID-UHFFFAOYSA-N 0.000 claims description 2
- RUCVPUYGOWHOCS-UHFFFAOYSA-N 2-[2-bromo-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]butanoic acid Chemical compound C1=C(Br)C(OC(CC)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 RUCVPUYGOWHOCS-UHFFFAOYSA-N 0.000 claims description 2
- ZAIHXNBXBUBWJH-UHFFFAOYSA-N 2-[3-chloro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC1=CC(OC(C)(C)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 ZAIHXNBXBUBWJH-UHFFFAOYSA-N 0.000 claims description 2
- FOTKREGBTRGTMN-UHFFFAOYSA-N 2-[4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]acetic acid Chemical compound C1=CC(OCC(=O)O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 FOTKREGBTRGTMN-UHFFFAOYSA-N 0.000 claims description 2
- UPBKMKAQHBYUHD-UHFFFAOYSA-N 2-methyl-2-[2-methyl-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]propanoic acid Chemical compound C1=C(OC(C)(C)C(O)=O)C(C)=CC(CCC(=O)C=2SC(=CC=2)C=2C=CC(=CC=2)C(F)(F)F)=C1 UPBKMKAQHBYUHD-UHFFFAOYSA-N 0.000 claims description 2
- 206010052895 Coronary artery insufficiency Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000001088 anti-asthma Effects 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 230000002253 anti-ischaemic effect Effects 0.000 claims description 2
- 239000000883 anti-obesity agent Substances 0.000 claims description 2
- 239000000924 antiasthmatic agent Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940125710 antiobesity agent Drugs 0.000 claims description 2
- 229940127218 antiplatelet drug Drugs 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- UHBUPZLWEGLZAH-UHFFFAOYSA-N ethyl 2-[2,3-dichloro-4-[3-hydroxy-3-[5-[3-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoate Chemical compound ClC1=C(Cl)C(OC(C)(C)C(=O)OCC)=CC=C1CCC(O)C1=CC=C(C=2C=C(C=CC=2)C(F)(F)F)S1 UHBUPZLWEGLZAH-UHFFFAOYSA-N 0.000 claims description 2
- 230000000871 hypocholesterolemic effect Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 125000006513 pyridinyl methyl group Chemical group 0.000 claims description 2
- 239000012453 solvate Chemical group 0.000 claims description 2
- LVHBTQSDUIQWAX-UHFFFAOYSA-N tert-butyl 2-[2,3-dichloro-4-[3-oxo-3-[4-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoate Chemical compound ClC1=C(Cl)C(OC(C)(C)C(=O)OC(C)(C)C)=CC=C1CCC(=O)C1=CC(C=2C=CC(=CC=2)C(F)(F)F)=CS1 LVHBTQSDUIQWAX-UHFFFAOYSA-N 0.000 claims description 2
- SZCWUEKSDMHOQC-UHFFFAOYSA-N tert-butyl 2-[2,3-dichloro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]furan-2-yl]propyl]phenoxy]-2-methylpropanoate Chemical compound ClC1=C(Cl)C(OC(C)(C)C(=O)OC(C)(C)C)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)O1 SZCWUEKSDMHOQC-UHFFFAOYSA-N 0.000 claims description 2
- XOGAMENLCNNSLF-UHFFFAOYSA-N tert-butyl 2-[2,3-difluoro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoate Chemical compound FC1=C(F)C(OC(C)(C)C(=O)OC(C)(C)C)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 XOGAMENLCNNSLF-UHFFFAOYSA-N 0.000 claims description 2
- JFFXYHHBCRZEHZ-UHFFFAOYSA-N tert-butyl 2-[2-chloro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoate Chemical compound C1=C(Cl)C(OC(C)(C)C(=O)OC(C)(C)C)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 JFFXYHHBCRZEHZ-UHFFFAOYSA-N 0.000 claims description 2
- ZDBDECGRFVINNF-UHFFFAOYSA-N tert-butyl 2-[2-fluoro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]acetate Chemical compound C1=C(F)C(OCC(=O)OC(C)(C)C)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 ZDBDECGRFVINNF-UHFFFAOYSA-N 0.000 claims description 2
- HCVSAQDYZVPDNL-UHFFFAOYSA-N tert-butyl 2-[2-fluoro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]butanoate Chemical compound C1=C(F)C(OC(CC)C(=O)OC(C)(C)C)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 HCVSAQDYZVPDNL-UHFFFAOYSA-N 0.000 claims description 2
- STQRDBCPNHXYLD-UHFFFAOYSA-N tert-butyl 2-[3-chloro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoate Chemical compound ClC1=CC(OC(C)(C)C(=O)OC(C)(C)C)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 STQRDBCPNHXYLD-UHFFFAOYSA-N 0.000 claims description 2
- NBTMOYMHMAQNAN-UHFFFAOYSA-N tert-butyl 2-[4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]butanoate Chemical compound C1=CC(OC(CC)C(=O)OC(C)(C)C)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 NBTMOYMHMAQNAN-UHFFFAOYSA-N 0.000 claims description 2
- CRCKZQLWUIXTIP-UHFFFAOYSA-N tert-butyl 2-methyl-2-[4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]propanoate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)(C)C)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 CRCKZQLWUIXTIP-UHFFFAOYSA-N 0.000 claims description 2
- UVPWLTQCJLEMIT-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-(cyclohexylmethoxy)-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(C=1SC(=CC=1)C=1C=CC(=CC=1)C(F)(F)F)OCC1CCCCC1 UVPWLTQCJLEMIT-UHFFFAOYSA-N 0.000 claims 1
- HTNZGDOIFIBZQK-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]butanoic acid Chemical compound ClC1=C(Cl)C(OC(CC)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 HTNZGDOIFIBZQK-UHFFFAOYSA-N 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- RLNDNTKJJYDGKF-UHFFFAOYSA-N tert-butyl 2-[2,3-dichloro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]butanoate Chemical compound ClC1=C(Cl)C(OC(CC)C(=O)OC(C)(C)C)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 RLNDNTKJJYDGKF-UHFFFAOYSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 36
- 230000036541 health Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 288
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 257
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 219
- 238000001704 evaporation Methods 0.000 description 202
- 230000008020 evaporation Effects 0.000 description 202
- 238000000034 method Methods 0.000 description 132
- 230000014509 gene expression Effects 0.000 description 126
- 238000005481 NMR spectroscopy Methods 0.000 description 120
- 230000002829 reductive effect Effects 0.000 description 113
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 112
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
- 238000010828 elution Methods 0.000 description 98
- 108090000623 proteins and genes Proteins 0.000 description 96
- 239000000741 silica gel Substances 0.000 description 90
- 229910002027 silica gel Inorganic materials 0.000 description 90
- 238000003756 stirring Methods 0.000 description 87
- 239000000377 silicon dioxide Substances 0.000 description 82
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 76
- 238000004587 chromatography analysis Methods 0.000 description 73
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 68
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 62
- 229940125782 compound 2 Drugs 0.000 description 62
- 241000699670 Mus sp. Species 0.000 description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- 239000000243 solution Substances 0.000 description 49
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
- 239000012074 organic phase Substances 0.000 description 47
- 235000012000 cholesterol Nutrition 0.000 description 44
- 239000002904 solvent Substances 0.000 description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 43
- 230000000694 effects Effects 0.000 description 40
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 39
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 38
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 35
- 108010023302 HDL Cholesterol Proteins 0.000 description 35
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 34
- 235000019341 magnesium sulphate Nutrition 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 33
- 239000000543 intermediate Substances 0.000 description 33
- 239000002609 medium Substances 0.000 description 33
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- 230000000692 anti-sense effect Effects 0.000 description 30
- 230000006698 induction Effects 0.000 description 29
- 239000012429 reaction media Substances 0.000 description 29
- 238000001727 in vivo Methods 0.000 description 28
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 27
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 25
- 102000000018 Chemokine CCL2 Human genes 0.000 description 25
- 210000002027 skeletal muscle Anatomy 0.000 description 25
- 108010015181 PPAR delta Proteins 0.000 description 24
- 102100034825 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Human genes 0.000 description 23
- 238000005259 measurement Methods 0.000 description 23
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 22
- 108010083885 pyruvate dehydrogenase kinase 4 Proteins 0.000 description 21
- 150000001720 carbohydrates Chemical class 0.000 description 20
- 235000014633 carbohydrates Nutrition 0.000 description 20
- 230000003213 activating effect Effects 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 19
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 18
- 238000009826 distribution Methods 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 18
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 17
- 239000003054 catalyst Substances 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 17
- 238000003818 flash chromatography Methods 0.000 description 17
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 17
- 238000003753 real-time PCR Methods 0.000 description 17
- 150000003626 triacylglycerols Chemical class 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 238000001914 filtration Methods 0.000 description 15
- 210000001616 monocyte Anatomy 0.000 description 15
- 210000003205 muscle Anatomy 0.000 description 15
- 108020004635 Complementary DNA Proteins 0.000 description 14
- 238000010804 cDNA synthesis Methods 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 14
- 235000014113 dietary fatty acids Nutrition 0.000 description 14
- 229930195729 fatty acid Natural products 0.000 description 14
- 239000000194 fatty acid Substances 0.000 description 14
- 150000004665 fatty acids Chemical class 0.000 description 14
- 230000004936 stimulating effect Effects 0.000 description 14
- 241001529936 Murinae Species 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- 210000005228 liver tissue Anatomy 0.000 description 13
- 210000002540 macrophage Anatomy 0.000 description 13
- 230000021715 photosynthesis, light harvesting Effects 0.000 description 13
- 239000012312 sodium hydride Substances 0.000 description 13
- 229910000104 sodium hydride Inorganic materials 0.000 description 13
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 13
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 102000004895 Lipoproteins Human genes 0.000 description 12
- 108090001030 Lipoproteins Proteins 0.000 description 12
- 108010029485 Protein Isoforms Proteins 0.000 description 12
- 102000001708 Protein Isoforms Human genes 0.000 description 12
- 239000000556 agonist Substances 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 230000002503 metabolic effect Effects 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 11
- 108010007622 LDL Lipoproteins Proteins 0.000 description 11
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 11
- 102000023984 PPAR alpha Human genes 0.000 description 11
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 11
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 11
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 11
- 235000021588 free fatty acids Nutrition 0.000 description 11
- 230000004060 metabolic process Effects 0.000 description 11
- 210000000107 myocyte Anatomy 0.000 description 11
- 238000007254 oxidation reaction Methods 0.000 description 11
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 11
- 238000002953 preparative HPLC Methods 0.000 description 11
- 238000003757 reverse transcription PCR Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 108010010234 HDL Lipoproteins Proteins 0.000 description 10
- 102000015779 HDL Lipoproteins Human genes 0.000 description 10
- 102000007330 LDL Lipoproteins Human genes 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 230000004069 differentiation Effects 0.000 description 10
- 238000007824 enzymatic assay Methods 0.000 description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 10
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 9
- 208000017170 Lipid metabolism disease Diseases 0.000 description 9
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 9
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 239000012894 fetal calf serum Substances 0.000 description 9
- IGVNJALYNQVQIT-UHFFFAOYSA-N tert-butyl 2-bromo-2-methylpropanoate Chemical compound CC(C)(C)OC(=O)C(C)(C)Br IGVNJALYNQVQIT-UHFFFAOYSA-N 0.000 description 9
- 230000032258 transport Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 102000000536 PPAR gamma Human genes 0.000 description 8
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 108010021098 Uncoupling Protein 3 Proteins 0.000 description 8
- 235000019270 ammonium chloride Nutrition 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 229910052731 fluorine Inorganic materials 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000012047 saturated solution Substances 0.000 description 8
- GEORDJYJYUGGSO-UHFFFAOYSA-N 2,3-dichloro-4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C(Cl)=C1Cl GEORDJYJYUGGSO-UHFFFAOYSA-N 0.000 description 7
- 101150092476 ABCA1 gene Proteins 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 108010016731 PPAR gamma Proteins 0.000 description 7
- 102000008200 Uncoupling Protein 3 Human genes 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000010839 reverse transcription Methods 0.000 description 7
- 239000003161 ribonuclease inhibitor Substances 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000028016 temperature homeostasis Effects 0.000 description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- BJQZMUPNZWLRMA-UHFFFAOYSA-N 1-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]ethanone Chemical compound S1C(C(=O)C)=CC=C1C1=CC=C(C(F)(F)F)C=C1 BJQZMUPNZWLRMA-UHFFFAOYSA-N 0.000 description 5
- OSHPCEQPBSFXJD-UHFFFAOYSA-N 3-(2,3-dichloro-4-hydroxyphenyl)-1-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propan-1-one Chemical compound ClC1=C(Cl)C(O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 OSHPCEQPBSFXJD-UHFFFAOYSA-N 0.000 description 5
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 0 CCC(C(OC(C)(C)C)=O)Oc(ccc(CCC(c1ccc(-c(cc2)ccc2C(F)=*)[s]1)=O)c1Cl)c1Cl Chemical compound CCC(C(OC(C)(C)C)=O)Oc(ccc(CCC(c1ccc(-c(cc2)ccc2C(F)=*)[s]1)=O)c1Cl)c1Cl 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- UMYZHWLYICNGRQ-UHFFFAOYSA-N ethanol;heptane Chemical compound CCO.CCCCCCC UMYZHWLYICNGRQ-UHFFFAOYSA-N 0.000 description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 4
- BOQTVQQVGTVILS-UHFFFAOYSA-N 1-[5-(4-bromophenyl)thiophen-2-yl]-3-(2,3-dichloro-4-hydroxyphenyl)prop-2-en-1-one Chemical compound ClC1=C(Cl)C(O)=CC=C1C=CC(=O)C1=CC=C(C=2C=CC(Br)=CC=2)S1 BOQTVQQVGTVILS-UHFFFAOYSA-N 0.000 description 4
- MWKZIJKRJORRGW-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 MWKZIJKRJORRGW-UHFFFAOYSA-N 0.000 description 4
- FIZXRXOGHYSYFG-UHFFFAOYSA-N 3-(3-bromo-4-hydroxyphenyl)-1-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propan-1-one Chemical compound C1=C(Br)C(O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 FIZXRXOGHYSYFG-UHFFFAOYSA-N 0.000 description 4
- JLPWRVSFYDHALW-UHFFFAOYSA-N 3-(4-hydroxy-3,5-dimethylphenyl)-1-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propan-1-one Chemical compound CC1=C(O)C(C)=CC(CCC(=O)C=2SC(=CC=2)C=2C=CC(=CC=2)C(F)(F)F)=C1 JLPWRVSFYDHALW-UHFFFAOYSA-N 0.000 description 4
- 102000055510 ATP Binding Cassette Transporter 1 Human genes 0.000 description 4
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 description 4
- 108010001515 Galectin 4 Proteins 0.000 description 4
- 102100039556 Galectin-4 Human genes 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- FTHDNRBKSLBLDA-UHFFFAOYSA-N cyclohexane-1,3,5-tricarboxylic acid Chemical compound OC(=O)C1CC(C(O)=O)CC(C(O)=O)C1 FTHDNRBKSLBLDA-UHFFFAOYSA-N 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 229960004586 rosiglitazone Drugs 0.000 description 4
- 235000000891 standard diet Nutrition 0.000 description 4
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 4
- RIUJWUWLGXBICR-UHFFFAOYSA-N tert-butyl 2-bromobutanoate Chemical compound CCC(Br)C(=O)OC(C)(C)C RIUJWUWLGXBICR-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 239000003451 thiazide diuretic agent Substances 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 3
- RNENYJYSRLPCPQ-UHFFFAOYSA-N 1-[5-(4-bromophenyl)thiophen-2-yl]ethanone Chemical compound S1C(C(=O)C)=CC=C1C1=CC=C(Br)C=C1 RNENYJYSRLPCPQ-UHFFFAOYSA-N 0.000 description 3
- CKFSODRXUIDCRK-UHFFFAOYSA-N 1-[5-(4-methylsulfanylphenyl)thiophen-2-yl]ethanone Chemical compound C1=CC(SC)=CC=C1C1=CC=C(C(C)=O)S1 CKFSODRXUIDCRK-UHFFFAOYSA-N 0.000 description 3
- UNONWHVCZIDGFO-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-hydroxy-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 UNONWHVCZIDGFO-UHFFFAOYSA-N 0.000 description 3
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 3
- XHQKQKHLYVRYLO-UHFFFAOYSA-N 3-(2,3-dichloro-4-hydroxyphenyl)-1-[4-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propan-1-one Chemical compound ClC1=C(Cl)C(O)=CC=C1CCC(=O)C1=CC(C=2C=CC(=CC=2)C(F)(F)F)=CS1 XHQKQKHLYVRYLO-UHFFFAOYSA-N 0.000 description 3
- XVJAUBNCZBXMLH-UHFFFAOYSA-N 3-(2,3-difluoro-4-hydroxyphenyl)-1-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propan-1-one Chemical compound FC1=C(F)C(O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 XVJAUBNCZBXMLH-UHFFFAOYSA-N 0.000 description 3
- XXLWKDDXVAWGHZ-UHFFFAOYSA-N 3-(2-chloro-4-hydroxyphenyl)-1-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propan-1-one Chemical compound ClC1=CC(O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 XXLWKDDXVAWGHZ-UHFFFAOYSA-N 0.000 description 3
- KJLVJLSORYJIFT-UHFFFAOYSA-N 5-[2,3-dichloro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2,2-dimethylpentanoic acid Chemical compound ClC1=C(Cl)C(OCCCC(C)(C)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 KJLVJLSORYJIFT-UHFFFAOYSA-N 0.000 description 3
- 108010071619 Apolipoproteins Proteins 0.000 description 3
- 102000007592 Apolipoproteins Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 101150080763 Mcpt1 gene Proteins 0.000 description 3
- 102000003939 Membrane transport proteins Human genes 0.000 description 3
- 108090000301 Membrane transport proteins Proteins 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 229960002274 atenolol Drugs 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 229940097320 beta blocking agent Drugs 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 125000000062 cyclohexylmethoxy group Chemical group [H]C([H])(O*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 150000004678 hydrides Chemical class 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000010829 isocratic elution Methods 0.000 description 3
- 229960001632 labetalol Drugs 0.000 description 3
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 3
- 229960002237 metoprolol Drugs 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 230000003387 muscular Effects 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 229960003712 propranolol Drugs 0.000 description 3
- 238000011894 semi-preparative HPLC Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000000825 ultraviolet detection Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 2
- LENAVORGWBTPJR-UHFFFAOYSA-N (5-pyridin-3-ylfuran-2-yl)methanamine Chemical compound O1C(CN)=CC=C1C1=CC=CN=C1 LENAVORGWBTPJR-UHFFFAOYSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CASNGOWLOZSVMA-UHFFFAOYSA-N 1-(5-bromofuran-2-yl)ethanone Chemical compound CC(=O)C1=CC=C(Br)O1 CASNGOWLOZSVMA-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- BZQMYJWWAAKLPL-UHFFFAOYSA-N 1-[5-(4-bromophenyl)thiophen-2-yl]-3-(2,3-dichloro-4-hydroxyphenyl)propan-1-one Chemical compound ClC1=C(Cl)C(O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(Br)=CC=2)S1 BZQMYJWWAAKLPL-UHFFFAOYSA-N 0.000 description 2
- KZHJKWBXJOUOSU-UHFFFAOYSA-N 1-[5-[3-(trifluoromethyl)phenyl]thiophen-2-yl]ethanone Chemical compound S1C(C(=O)C)=CC=C1C1=CC=CC(C(F)(F)F)=C1 KZHJKWBXJOUOSU-UHFFFAOYSA-N 0.000 description 2
- NXXYKOUNUYWIHA-UHFFFAOYSA-N 2,6-Dimethylphenol Chemical compound CC1=CC=CC(C)=C1O NXXYKOUNUYWIHA-UHFFFAOYSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- ZVDRGWJVHBWPGB-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-oxo-3-[5-[4-(trifluoromethoxy)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(OC(F)(F)F)=CC=2)S1 ZVDRGWJVHBWPGB-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- QBFDKXYMSDLVBD-UHFFFAOYSA-N 3-(2,3-dichloro-4-hydroxyphenyl)-1-(5-phenylthiophen-2-yl)propan-1-one Chemical compound ClC1=C(Cl)C(O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC=CC=2)S1 QBFDKXYMSDLVBD-UHFFFAOYSA-N 0.000 description 2
- LOVYAQYKECKRDZ-UHFFFAOYSA-N 3-(2,3-dichloro-4-hydroxyphenyl)-1-[5-(4-methylsulfanylphenyl)thiophen-2-yl]prop-2-en-1-one Chemical compound C1=CC(SC)=CC=C1C1=CC=C(C(=O)C=CC=2C(=C(Cl)C(O)=CC=2)Cl)S1 LOVYAQYKECKRDZ-UHFFFAOYSA-N 0.000 description 2
- QAJQRLGTPJHWAS-UHFFFAOYSA-N 3-(2,3-dichloro-4-hydroxyphenyl)-1-[5-[4-(trifluoromethoxy)phenyl]thiophen-2-yl]propan-1-one Chemical compound ClC1=C(Cl)C(O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(OC(F)(F)F)=CC=2)S1 QAJQRLGTPJHWAS-UHFFFAOYSA-N 0.000 description 2
- LLAHGWMQWZHWLM-UHFFFAOYSA-N 3-(2,3-dichloro-4-hydroxyphenyl)-1-[5-[4-(trifluoromethyl)phenyl]furan-2-yl]propan-1-one Chemical compound ClC1=C(Cl)C(O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)O1 LLAHGWMQWZHWLM-UHFFFAOYSA-N 0.000 description 2
- SXXCNQUMAIOKKD-UHFFFAOYSA-N 3-(3-bromo-4-hydroxyphenyl)-1-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]prop-2-en-1-one Chemical compound C1=C(Br)C(O)=CC=C1C=CC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 SXXCNQUMAIOKKD-UHFFFAOYSA-N 0.000 description 2
- SKYWIEOWMGDZKM-UHFFFAOYSA-N 3-(3-chloro-4-hydroxyphenyl)-1-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propan-1-one Chemical compound C1=C(Cl)C(O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 SKYWIEOWMGDZKM-UHFFFAOYSA-N 0.000 description 2
- LBIUCLBUIGBXNG-UHFFFAOYSA-N 3-(3-fluoro-4-hydroxyphenyl)-1-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]prop-2-en-1-one Chemical compound C1=C(F)C(O)=CC=C1C=CC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 LBIUCLBUIGBXNG-UHFFFAOYSA-N 0.000 description 2
- ZOIXPGYCTPCIPY-UHFFFAOYSA-N 3-(3-fluoro-4-hydroxyphenyl)-1-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propan-1-one Chemical compound C1=C(F)C(O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 ZOIXPGYCTPCIPY-UHFFFAOYSA-N 0.000 description 2
- YMBXMTPYRWJCCC-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-1-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]prop-2-en-1-one Chemical compound C1=CC(O)=CC=C1C=CC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 YMBXMTPYRWJCCC-UHFFFAOYSA-N 0.000 description 2
- YNBNKLVFMQSSFW-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-1-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propan-1-one Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 YNBNKLVFMQSSFW-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- UOTMHAOCAJROQF-UHFFFAOYSA-N 3-bromo-4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1Br UOTMHAOCAJROQF-UHFFFAOYSA-N 0.000 description 2
- UYGBSRJODQHNLQ-UHFFFAOYSA-N 4-hydroxy-3,5-dimethylbenzaldehyde Chemical compound CC1=CC(C=O)=CC(C)=C1O UYGBSRJODQHNLQ-UHFFFAOYSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- LDIOUQIXNSSOGU-UHFFFAOYSA-N 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5h-cyclopenta[d]pyrazolo[1,5-a]pyrimidine Chemical compound CC1=NN2C(NC(CC)CC)=C3CCCC3=NC2=C1C1=CC=C(OC)C=C1Cl LDIOUQIXNSSOGU-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 108010060219 Apolipoprotein E2 Proteins 0.000 description 2
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- 208000024412 Friedreich ataxia Diseases 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 229940126033 PPAR agonist Drugs 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 102000053067 Pyruvate Dehydrogenase Acetyl-Transferring Kinase Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- 208000034799 Tauopathies Diseases 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 108010069201 VLDL Cholesterol Proteins 0.000 description 2
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 101710143997 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Proteins 0.000 description 2
- 101710159466 [Pyruvate dehydrogenase (acetyl-transferring)] kinase, mitochondrial Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002170 aldosterone antagonist Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 229960000528 amlodipine Drugs 0.000 description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- BOWQDFRKKXVCCI-UHFFFAOYSA-N butyl 2-bromo-2-methylpropanoate Chemical group CCCCOC(=O)C(C)(C)Br BOWQDFRKKXVCCI-UHFFFAOYSA-N 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 208000025434 cerebellar degeneration Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229960003580 felodipine Drugs 0.000 description 2
- 229960002297 fenofibrate Drugs 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- 229960000701 fenofibric acid Drugs 0.000 description 2
- MQOBSOSZFYZQOK-UHFFFAOYSA-N fenofibric acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 MQOBSOSZFYZQOK-UHFFFAOYSA-N 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 229960003883 furosemide Drugs 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 229960003627 gemfibrozil Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000014101 glucose homeostasis Effects 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 230000009716 hepatic expression Effects 0.000 description 2
- CLUPOLFGIGLMIQ-UHFFFAOYSA-N heptane;propan-2-ol Chemical compound CC(C)O.CCCCCCC CLUPOLFGIGLMIQ-UHFFFAOYSA-N 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 229960002003 hydrochlorothiazide Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 2
- 229960004569 indapamide Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- NTRGLWIDBQJWHF-UHFFFAOYSA-N methyl 5-[2,3-dichloro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2,2-dimethylpentanoate Chemical compound ClC1=C(Cl)C(OCCCC(C)(C)C(=O)OC)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 NTRGLWIDBQJWHF-UHFFFAOYSA-N 0.000 description 2
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 2
- VQSRKMNBWMHJKY-YTEVENLXSA-N n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H](CN(C2)C=2N=CC(F)=CN=2)CSC(N)=N3)=C1 VQSRKMNBWMHJKY-YTEVENLXSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229960001455 quinapril Drugs 0.000 description 2
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 229960003401 ramipril Drugs 0.000 description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- FPFPUKNGEDUVLA-UHFFFAOYSA-N s-(trifluoromethyl)thiohydroxylamine Chemical class NSC(F)(F)F FPFPUKNGEDUVLA-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- OOTFGLBGVYDPNB-UHFFFAOYSA-N tert-butyl 2-[2-fluoro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoate Chemical compound C1=C(F)C(OC(C)(C)C(=O)OC(C)(C)C)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 OOTFGLBGVYDPNB-UHFFFAOYSA-N 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- ZXEIEKDGPVTZLD-NDEPHWFRSA-N (2s)-2-dodecylsulfanyl-n-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetamide Chemical compound O=C([C@@H](SCCCCCCCCCCCC)C=1C=CC=CC=1)NC1=CC(C)=C(O)C(C)=C1C ZXEIEKDGPVTZLD-NDEPHWFRSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- SRKGZXIJDGWVAI-GVAVTCRGSA-M (e,3r)-7-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)C1=NC(C(C)(C)C)=CC(C=2C=CC(F)=CC=2)=C1\C=C\C(O)C[C@@H](O)CC([O-])=O SRKGZXIJDGWVAI-GVAVTCRGSA-M 0.000 description 1
- ZYZCALPXKGUGJI-DDVDASKDSA-M (e,3r,5s)-7-[3-(4-fluorophenyl)-2-phenyl-5-propan-2-ylimidazol-4-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C=1C=C(F)C=CC=1N1C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C(C)C)N=C1C1=CC=CC=C1 ZYZCALPXKGUGJI-DDVDASKDSA-M 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- HXVLWNKFMNRJED-UHFFFAOYSA-N 1-(4-bromothiophen-2-yl)ethanone Chemical compound CC(=O)C1=CC(Br)=CS1 HXVLWNKFMNRJED-UHFFFAOYSA-N 0.000 description 1
- IGBZCOWXSCWSHO-UHFFFAOYSA-N 1-(5-bromothiophen-2-yl)ethanone Chemical compound CC(=O)C1=CC=C(Br)S1 IGBZCOWXSCWSHO-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- TVKGHICMBMWEKN-UHFFFAOYSA-N 1-[4-[4-(trifluoromethyl)phenyl]thiophen-2-yl]ethanone Chemical compound S1C(C(=O)C)=CC(C=2C=CC(=CC=2)C(F)(F)F)=C1 TVKGHICMBMWEKN-UHFFFAOYSA-N 0.000 description 1
- IHMIQKJNHLRUSQ-UHFFFAOYSA-N 1-[5-[4-(trifluoromethoxy)phenyl]thiophen-2-yl]ethanone Chemical compound S1C(C(=O)C)=CC=C1C1=CC=C(OC(F)(F)F)C=C1 IHMIQKJNHLRUSQ-UHFFFAOYSA-N 0.000 description 1
- XLMXYVUYXGZXBK-UHFFFAOYSA-N 1-[5-[4-(trifluoromethyl)phenyl]furan-2-yl]ethanone Chemical compound O1C(C(=O)C)=CC=C1C1=CC=C(C(F)(F)F)C=C1 XLMXYVUYXGZXBK-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- XLQSXGGDTHANLN-UHFFFAOYSA-N 1-bromo-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(Br)C=C1 XLQSXGGDTHANLN-UHFFFAOYSA-N 0.000 description 1
- UCCUXODGPMAHRL-UHFFFAOYSA-N 1-bromo-4-iodobenzene Chemical compound BrC1=CC=C(I)C=C1 UCCUXODGPMAHRL-UHFFFAOYSA-N 0.000 description 1
- YEUYZNNBXLMFCW-UHFFFAOYSA-N 1-bromo-4-methylsulfanylbenzene Chemical compound CSC1=CC=C(Br)C=C1 YEUYZNNBXLMFCW-UHFFFAOYSA-N 0.000 description 1
- UMPSXRYVXUPCOS-UHFFFAOYSA-N 2,3-dichlorophenol Chemical compound OC1=CC=CC(Cl)=C1Cl UMPSXRYVXUPCOS-UHFFFAOYSA-N 0.000 description 1
- KTGPDDPEVRJSFY-UHFFFAOYSA-N 2,3-difluoro-4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C(F)=C1F KTGPDDPEVRJSFY-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- UKGANDMHOUCMAR-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-[(4-iodophenyl)methoxy]-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound ClC1=C(Cl)C(OC(C)(C)C(O)=O)=CC=C1CCC(C=1SC(=CC=1)C=1C=CC(=CC=1)C(F)(F)F)OCC1=CC=C(I)C=C1 UKGANDMHOUCMAR-UHFFFAOYSA-N 0.000 description 1
- QKHKPHLEFUZFSK-UHFFFAOYSA-N 2-[2,3-dichloro-4-[3-methoxyimino-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoic acid Chemical compound C=1C=C(C=2C=CC(=CC=2)C(F)(F)F)SC=1C(=NOC)CCC1=CC=C(OC(C)(C)C(O)=O)C(Cl)=C1Cl QKHKPHLEFUZFSK-UHFFFAOYSA-N 0.000 description 1
- OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical compound C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- IEMMBWWQXVXBEU-UHFFFAOYSA-N 2-acetylfuran Chemical compound CC(=O)C1=CC=CO1 IEMMBWWQXVXBEU-UHFFFAOYSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- HTFXWAOSQODIBI-UHFFFAOYSA-N 2-benzyl-1,3-dihydropyrrolo[3,4-c]pyridine Chemical compound C1C2=CC=NC=C2CN1CC1=CC=CC=C1 HTFXWAOSQODIBI-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- ZMOMCILMBYEGLD-UHFFFAOYSA-N 2-chloro-4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C(Cl)=C1 ZMOMCILMBYEGLD-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- BQDGYDWDXNSVMM-UHFFFAOYSA-N 2-phenyl-1-(3-phenylfuran-2-yl)propan-1-one Chemical class C1(=CC=CC=C1)C(C(=O)C=1OC=CC=1C1=CC=CC=C1)C BQDGYDWDXNSVMM-UHFFFAOYSA-N 0.000 description 1
- QDWLTQWBAGYTPJ-UHFFFAOYSA-N 3-(2,3-dichloro-4-hydroxyphenyl)-1-[5-(4-methylsulfanylphenyl)thiophen-2-yl]propan-1-one Chemical compound C1=CC(SC)=CC=C1C1=CC=C(C(=O)CCC=2C(=C(Cl)C(O)=CC=2)Cl)S1 QDWLTQWBAGYTPJ-UHFFFAOYSA-N 0.000 description 1
- CSMVAAOCFZJRSJ-UHFFFAOYSA-N 3-(2,3-dichloro-4-hydroxyphenyl)-1-[5-[3-(trifluoromethyl)phenyl]thiophen-2-yl]prop-2-en-1-one Chemical compound ClC1=C(Cl)C(O)=CC=C1C=CC(=O)C1=CC=C(C=2C=C(C=CC=2)C(F)(F)F)S1 CSMVAAOCFZJRSJ-UHFFFAOYSA-N 0.000 description 1
- ATTLNGTWOOLLKY-UHFFFAOYSA-N 3-(2,3-dichloro-4-hydroxyphenyl)-1-[5-[3-(trifluoromethyl)phenyl]thiophen-2-yl]propan-1-one Chemical compound ClC1=C(Cl)C(O)=CC=C1CCC(=O)C1=CC=C(C=2C=C(C=CC=2)C(F)(F)F)S1 ATTLNGTWOOLLKY-UHFFFAOYSA-N 0.000 description 1
- WPEJBJMLORDZJO-UHFFFAOYSA-N 3-(2,3-dichloro-4-hydroxyphenyl)-1-[5-[4-(trifluoromethoxy)phenyl]thiophen-2-yl]prop-2-en-1-one Chemical compound ClC1=C(Cl)C(O)=CC=C1C=CC(=O)C1=CC=C(C=2C=CC(OC(F)(F)F)=CC=2)S1 WPEJBJMLORDZJO-UHFFFAOYSA-N 0.000 description 1
- QAINWXOFYWOIBU-UHFFFAOYSA-N 3-(2,3-dichloro-4-hydroxyphenyl)-1-[5-[4-(trifluoromethyl)phenyl]furan-2-yl]prop-2-en-1-one Chemical compound ClC1=C(Cl)C(O)=CC=C1C=CC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)O1 QAINWXOFYWOIBU-UHFFFAOYSA-N 0.000 description 1
- JQYDSMLVBVUYFX-UHFFFAOYSA-N 3-(2-chloro-4-hydroxyphenyl)-1-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]prop-2-en-1-one Chemical compound ClC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 JQYDSMLVBVUYFX-UHFFFAOYSA-N 0.000 description 1
- MATOQVQBPZOPCD-UHFFFAOYSA-N 3-(3-chloro-4-hydroxyphenyl)-1-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]prop-2-en-1-one Chemical compound C1=C(Cl)C(O)=CC=C1C=CC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 MATOQVQBPZOPCD-UHFFFAOYSA-N 0.000 description 1
- WMZFCNIJJFDEEN-UHFFFAOYSA-N 3-(4-hydroxy-3,5-dimethylphenyl)-1-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]prop-2-en-1-one Chemical compound CC1=C(O)C(C)=CC(C=CC(=O)C=2SC(=CC=2)C=2C=CC(=CC=2)C(F)(F)F)=C1 WMZFCNIJJFDEEN-UHFFFAOYSA-N 0.000 description 1
- JTSUURLKVNQBRF-UHFFFAOYSA-N 3-(4-hydroxy-3-methylphenyl)-1-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]prop-2-en-1-one Chemical compound C1=C(O)C(C)=CC(C=CC(=O)C=2SC(=CC=2)C=2C=CC(=CC=2)C(F)(F)F)=C1 JTSUURLKVNQBRF-UHFFFAOYSA-N 0.000 description 1
- VGSOCYWCRMXQAB-UHFFFAOYSA-N 3-chloro-4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1Cl VGSOCYWCRMXQAB-UHFFFAOYSA-N 0.000 description 1
- QSBHJTCAPWOIIE-UHFFFAOYSA-N 3-fluoro-4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1F QSBHJTCAPWOIIE-UHFFFAOYSA-N 0.000 description 1
- OWYLAEYXIQKAOL-UHFFFAOYSA-N 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone Chemical compound COC1=CC(OC)=CC(OC)=C1C(=O)CCCN1CCCC1 OWYLAEYXIQKAOL-UHFFFAOYSA-N 0.000 description 1
- BAKYASSDAXQKKY-UHFFFAOYSA-N 4-Hydroxy-3-methylbenzaldehyde Chemical compound CC1=CC(C=O)=CC=C1O BAKYASSDAXQKKY-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 1
- NFALWHMESUMVKK-UHFFFAOYSA-N 5-[4-(trifluoromethyl)phenyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1C1=CC=C(C(F)(F)F)C=C1 NFALWHMESUMVKK-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101150014984 ACO gene Proteins 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- JQJPBYFTQAANLE-UHFFFAOYSA-N Butyl nitrite Chemical compound CCCCON=O JQJPBYFTQAANLE-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- FFVMESPECGYAIU-UHFFFAOYSA-N CC(C)(C(=O)O)OC1=C(C(=C(C=C1)CCC(=NOC)C2=CC=C(S2)C3=CC=C(C=C3)CC(F)(F)F)Cl)Cl Chemical compound CC(C)(C(=O)O)OC1=C(C(=C(C=C1)CCC(=NOC)C2=CC=C(S2)C3=CC=C(C=C3)CC(F)(F)F)Cl)Cl FFVMESPECGYAIU-UHFFFAOYSA-N 0.000 description 1
- VFEAKKMEOPCHQX-UHFFFAOYSA-N CC(C)(C)C1=C(C(=C(C=C1CCC(=O)C2=CC=C(S2)C3=CC=C(C=C3)Br)OC(C)(C)C(=O)O)Cl)Cl Chemical compound CC(C)(C)C1=C(C(=C(C=C1CCC(=O)C2=CC=C(S2)C3=CC=C(C=C3)Br)OC(C)(C)C(=O)O)Cl)Cl VFEAKKMEOPCHQX-UHFFFAOYSA-N 0.000 description 1
- TTWBTLHMWCZRCP-UHFFFAOYSA-N CC(C)(C)OC(COc(ccc(CCC(c1ccc(-c2ccc(C(F)(F)F)cc2)[s]1)=O)c1Cl)c1Cl)=O Chemical compound CC(C)(C)OC(COc(ccc(CCC(c1ccc(-c2ccc(C(F)(F)F)cc2)[s]1)=O)c1Cl)c1Cl)=O TTWBTLHMWCZRCP-UHFFFAOYSA-N 0.000 description 1
- TXHITXMWAGGELD-UHFFFAOYSA-N CCCc(ccc(OC(C)(C)C(O)=O)c1Cl)c1Cl Chemical compound CCCc(ccc(OC(C)(C)C(O)=O)c1Cl)c1Cl TXHITXMWAGGELD-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- WWMGRCDYLDCOAU-UHFFFAOYSA-N CCOC(C(C)(C)Oc(ccc(CCC(c1ccc(C(C2)=CC=CC2C(F)(F)F)[s]1)O)c1Cl)c1Cl)=O Chemical compound CCOC(C(C)(C)Oc(ccc(CCC(c1ccc(C(C2)=CC=CC2C(F)(F)F)[s]1)O)c1Cl)c1Cl)=O WWMGRCDYLDCOAU-UHFFFAOYSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 description 1
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
- 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 description 1
- 101710120614 Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 1
- 101710108984 Carnitine O-palmitoyltransferase 1, muscle isoform Proteins 0.000 description 1
- 102100024853 Carnitine O-palmitoyltransferase 2, mitochondrial Human genes 0.000 description 1
- JTSUURLKVNQBRF-YCRREMRBSA-N Cc(cc(/C=C/C(c1ccc(-c2ccc(C(F)(F)F)cc2)[s]1)=O)cc1)c1O Chemical compound Cc(cc(/C=C/C(c1ccc(-c2ccc(C(F)(F)F)cc2)[s]1)=O)cc1)c1O JTSUURLKVNQBRF-YCRREMRBSA-N 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 1
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 1
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 101000771674 Homo sapiens Apolipoprotein E Proteins 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 1
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 1
- 101000833892 Homo sapiens Peroxisomal acyl-coenzyme A oxidase 1 Proteins 0.000 description 1
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 description 1
- 101000741797 Homo sapiens Peroxisome proliferator-activated receptor delta Proteins 0.000 description 1
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 1
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 108010020056 Hydrogenase Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- KBAFPSLPKGSANY-UHFFFAOYSA-N Naftidrofuryl Chemical compound C=1C=CC2=CC=CC=C2C=1CC(C(=O)OCCN(CC)CC)CC1CCCO1 KBAFPSLPKGSANY-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- BOQTVQQVGTVILS-XVNBXDOJSA-N Oc(ccc(/C=C/C(c1ccc(-c(cc2)ccc2Br)[s]1)=O)c1Cl)c1Cl Chemical compound Oc(ccc(/C=C/C(c1ccc(-c(cc2)ccc2Br)[s]1)=O)c1Cl)c1Cl BOQTVQQVGTVILS-XVNBXDOJSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 102100026798 Peroxisomal acyl-coenzyme A oxidase 1 Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 206010060751 Type III hyperlipidaemia Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- WOAORAPRPVIATR-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(C(F)(F)F)=C1 WOAORAPRPVIATR-UHFFFAOYSA-N 0.000 description 1
- ALMFIOZYDASRRC-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(C(F)(F)F)C=C1 ALMFIOZYDASRRC-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- OHRZXIJYFUZSJQ-UHFFFAOYSA-N [bromo(iodo)methyl]benzene Chemical compound BrC(I)C1=CC=CC=C1 OHRZXIJYFUZSJQ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000001720 action spectrum Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229960004663 alminoprofen Drugs 0.000 description 1
- FPHLBGOJWPEVME-UHFFFAOYSA-N alminoprofen Chemical compound OC(=O)C(C)C1=CC=C(NCC(C)=C)C=C1 FPHLBGOJWPEVME-UHFFFAOYSA-N 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- QZNJPJDUBTYMRS-UHFFFAOYSA-M amfenac sodium hydrate Chemical group O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=CC=C1 QZNJPJDUBTYMRS-UHFFFAOYSA-M 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 238000012443 analytical study Methods 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 229950010046 avasimibe Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
- 229960003665 bepridil Drugs 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- UUWSLBWDFJMSFP-UHFFFAOYSA-N bromomethylcyclohexane Chemical compound BrCC1CCCCC1 UUWSLBWDFJMSFP-UHFFFAOYSA-N 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960001415 buflomedil Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229940109248 cromoglycate Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-L cromoglycate(2-) Chemical compound O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-L 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000001258 dyslipidemic effect Effects 0.000 description 1
- 229950005925 eflucimibe Drugs 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 229960000972 enoximone Drugs 0.000 description 1
- ZJKNESGOIKRXQY-UHFFFAOYSA-N enoximone Chemical compound C1=CC(SC)=CC=C1C(=O)C1=C(C)NC(=O)N1 ZJKNESGOIKRXQY-UHFFFAOYSA-N 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- MZQXAVZPEZUJIJ-UHFFFAOYSA-N ethyl 2-(2-bromophenyl)acetate Chemical compound CCOC(=O)CC1=CC=CC=C1Br MZQXAVZPEZUJIJ-UHFFFAOYSA-N 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 102000053020 human ApoE Human genes 0.000 description 1
- 102000046768 human CCL2 Human genes 0.000 description 1
- 102000054223 human PPARA Human genes 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 125000006303 iodophenyl group Chemical group 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000006775 microglial inflammation Effects 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229950001135 muraglitazar Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960001132 naftidrofuryl Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229960004310 piribedil Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000207 pro-atherogenic effect Effects 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000028503 regulation of lipid metabolic process Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 1
- 229960003015 rimonabant Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960004034 sitagliptin Drugs 0.000 description 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229940075620 somatostatin analogue Drugs 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- YPKWRKGREYCKJH-UHFFFAOYSA-N tert-butyl 2-[2,3-dichloro-4-[3-hydroxy-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoate Chemical compound ClC1=C(Cl)C(OC(C)(C)C(=O)OC(C)(C)C)=CC=C1CCC(O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 YPKWRKGREYCKJH-UHFFFAOYSA-N 0.000 description 1
- RXDLBAKEZLWQKY-UHFFFAOYSA-N tert-butyl 2-[2,3-dichloro-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]-2-methylpropanoate Chemical compound ClC1=C(Cl)C(OC(C)(C)C(=O)OC(C)(C)C)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 RXDLBAKEZLWQKY-UHFFFAOYSA-N 0.000 description 1
- XLIHLNJGKASIPG-UHFFFAOYSA-N tert-butyl 2-[2-bromo-4-[3-oxo-3-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]propyl]phenoxy]acetate Chemical compound C1=C(Br)C(OCC(=O)OC(C)(C)C)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)S1 XLIHLNJGKASIPG-UHFFFAOYSA-N 0.000 description 1
- YLVGCRRDABYTLZ-UHFFFAOYSA-N tert-butyl 2-[4-[3-[5-(4-bromophenyl)thiophen-2-yl]-3-oxopropyl]-2,3-dichlorophenoxy]-2-methylpropanoate Chemical compound ClC1=C(Cl)C(OC(C)(C)C(=O)OC(C)(C)C)=CC=C1CCC(=O)C1=CC=C(C=2C=CC(Br)=CC=2)S1 YLVGCRRDABYTLZ-UHFFFAOYSA-N 0.000 description 1
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 description 1
- 229950004704 tesaglitazar Drugs 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- CMSGWTNRGKRWGS-NQIIRXRSSA-N torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 1
- 229950004514 torcetrapib Drugs 0.000 description 1
- GQHWSLKNULCZGI-UHFFFAOYSA-N trifluoromethoxybenzene Chemical compound FC(F)(F)OC1=CC=CC=C1 GQHWSLKNULCZGI-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to compounds derived from substituted 3-phenyl-1- (phenylthienyl) propan-1-one and 3-phenyl-1- (phenylfuranyl) propan-1-one, the pharmaceutical compositions comprising them and their therapeutic applications. , particularly in the areas of human and animal health.
- the inventors have surprisingly demonstrated that the compounds according to the invention intrinsically possess PPAR (Peroxisome Proliferator-Activated Receptor) agonist properties.
- PPAR Peroxisome Proliferator-Activated Receptor
- the molecules described in the invention are therefore of particular interest for treating complications associated with the metabolic syndrome, atherosclerosis, cardiovascular diseases, insulin resistance, obesity, hypertension, diabetes, dyslipidemias. , inflammatory diseases (asthma, etc.), cerebral ischemia, autoimmune diseases, neurodegenerative pathologies (Alzheimer's, etc.), cancers, etc., as well as to reduce the overall cardiovascular risk.
- the compounds according to the invention can be used for the treatment of dyslipidemias and improvement of the overall cardiovascular risk.
- Diabetes, obesity and dyslipidemia are among the clearly identified cardiovascular risk factors that predispose an individual to develop cardiovascular disease (Mensah M, 2004). These risk factors add up to lifestyle risk factors such as smoking, physical inactivity and unbalanced diets. A synergistic effect exists between these different factors: the concomitant presence of several of them leads to a dramatic worsening of the cardiovascular risk and it is then appropriate to speak of global risk ("global risk”) for cardiovascular diseases.
- the prevalence of dyslipidemia reached 43.6% of the population in 2004 in the major developed countries.
- the prevalence of diabetes, currently rising sharply, is becoming increasingly significant in the epidemiology of cardiovascular disease: the prevalence of diabetes is estimated at 7.6% of the population for 2010 (Fox-Tucker J, 2005).
- cardiovascular disease is the leading cause of death in industrialized countries and is becoming increasingly common in developing countries.
- diseases include coronary heart disease, cerebral ischemia and peripheral arterial diseases.
- the compounds according to the invention are of particular interest for the treatment of pathologies related to disorders of lipid and / or carbohydrate metabolism, such as diabetes, obesity, dyslipidemia or inflammation. , as well as for the reduction of the global cardiovascular risk.
- the PPARs ( ⁇ , ⁇ and ⁇ ) are in fact known to be involved in this type of pathology (Kota BP et al., 2005): ligands of these receptors are marketed to treat such pathologies (Lefebvre P et al., 2006) and many PPAR modulators, agonists or antagonists, selective or not, are currently in advanced pharmaceutical development.
- a PPAR modulator with beneficial effects on insulin resistance, obesity, dyslipidemia, hypertension and / or inflammation could be used in the treatment of metabolic syndrome (or syndrome X) (Liu Y and Miller A, 2005).
- the PPAR family comprises three isoforms, designated ⁇ , ⁇ and ⁇ (also called ⁇ ), each encoded by a different gene. These receptors are part of the superfamily of nuclear receptors and transcription that are activated by the binding of certain fatty acids and / or their lipid metabolites. Activated PPARs form heterodimers with retinoic acid receptors 9-cis (RXR or Retinoid X Receptor) and bind to specific response elements (PPRE or Peroxisome Proliferator Response Element) at the promoter of their target genes, thus allowing the control of the transcription.
- RXR or Retinoid X Receptor retinoic acid receptors 9-cis
- PPRE Peroxisome Proliferator Response Element
- PPAR ⁇ mainly controls lipid metabolism (hepatic and muscular) and glucose homeostasis, by directly controlling the transcription of genes encoding proteins involved in lipid homeostasis. It exerts anti-inflammatory and anti-proliferative effects and prevents the pro-atherogenic effects of cholesterol accumulation in macrophages by stimulating cholesterol efflux (Lefebvre P, Chinetti G, JC Fruchart and Staels B, 2006). Fibrates (fenofibrate, bezafibrate, ciprofibrate, gemfibrozil), via PPAR ⁇ , are thus used clinically in the treatment of certain dyslipidemias by lowering triglycerides and increasing plasma levels of HDL cholesterol (High Density Lipoprotein).
- PPAR ⁇ is involved in the lipid metabolism of mature adipocytes (key regulator of adipogenesis), in glucose homeostasis (especially in insulin resistance), in inflammation, in the accumulation of cholesterol in the body. macrophages and in cell proliferation (Lehrke M and Lazar MA, 2005). PPAR ⁇ therefore plays a role in the pathogenesis of obesity, insulin resistance and diabetes.
- Thiazolidinediones Roslitazone, Troglitazone, etc. are PPAR ⁇ receptor ligands used in the treatment of type 2 diabetes.
- PPAR ⁇ ligands there are PPAR ⁇ ligands currently in clinical development (eg GW501516 (CAS Registry Number 317318-70-0)), but no PPAR ⁇ ligand is currently used as a drug.
- This receptor is an attractive target for the development of drugs that can be used in the treatment of risk factors associated with metabolic syndrome and atherosclerosis such as dyslipidemia, obesity, inflammation and insulin resistance.
- PPAR ⁇ is indeed involved in the control of lipid and carbohydrate metabolism, in the energy balance, in the proliferation and differentiation of neurons, and in the inflammatory response (Gross B et al., 2005).
- PPAR ligands Beyond the direct role played by PPAR ligands on the regulation of lipid and carbohydrate metabolism, these molecules have a pleiotropic action spectrum due to the great diversity of PPAR target genes. These multiple properties make PPAR therapeutic targets of interest for the treatment of various pathologies, including cardio-metabolic pathologies (i.e. cardiovascular and metabolic pathologies) as well as to allow the reduction of global cardiovascular risk.
- cardio-metabolic pathologies i.e. cardiovascular and metabolic pathologies
- PPAR ligands have a neuroprotective role in Alzheimer's disease, multiple sclerosis, Parkinson's disease and more generally in any pathology involving death or neuronal degeneration, whether neurons of the central nervous system or peripheral, death or degeneration of oligodendrocytes, death or degeneration of glial cells, inflammation of glial cells (ie astrocytes, microglia or oligodendrocytes) or Schwann cells.
- PPAR ⁇ agonists have recently been shown to preserve learning and memory in rats for which Alzheimer's disease has been induced (Monte SM et al., 2006). It has also been shown that oral administration of PPAR ⁇ agonists reduces the clinical symptoms and activation of astroglial and microglial inflammation in a multiple sclerosis model (Polak, 2005).
- the compounds according to the invention by virtue of their PPAR agonist properties, therefore represent an advantageous therapeutic tool for the amelioration of pathologies related to disorders of lipid and / or carbohydrate metabolism, for the reduction of global cardiovascular risk as well as for neuroprotection.
- the compounds according to the invention possess PPAR ⁇ and PPAR ⁇ agonist properties and are therefore of interest in the treatment of metabolic pathologies such as the metabolic syndrome (whose characteristics are obesity (in particular abdominal obesity), a concentration abnormal blood lipids (high triglyceride levels and / or low HDL cholesterol (dyslipidemia), high blood glucose and / or insulin resistance and hypertension) and in the treatment of dyslipidemias.
- the metabolic syndrome whose characteristics are obesity (in particular abdominal obesity), a concentration abnormal blood lipids (high triglyceride levels and / or low HDL cholesterol (dyslipidemia), high blood glucose and / or insulin resistance and hypertension) and in the treatment of dyslipidemias.
- the subject of the present invention is compounds derived from 3-phenyl-1- (phenylthienyl) propan-1-one and substituted 3-phenyl-1 - (phenylfuranyl) propan-1-one of the following general formula (I):
- X1 represents a halogen, a group R1, -SR1 or -OR1;
- X 2 represents a sulfur or oxygen atom;
- X3 represents a halogen, a group R3, -SR3 or -OR3;
- X4 represents a halogen, a group R4, -SR4 or -OR4;
- X5 represents a group R5, -SR5 or -OR5;
- X6 represents a halogen, a group R6, -SR6 or -OR6;
- X7 represents a halogen, a group R7, -SR7 or -OR7;
- X8 represents an R8 group;
- R5 represents an alkyl group substituted with one or more substituents of group 1 or group 2; R5 may, in addition to the substitutions or substitutions described above, be substituted by a cycloalkyl, heterocycloalkyl, aryl or heteroaryl group as defined below;
- A represents:
- a group -CR9R10, R9 and R10 different representing a hydrogen, an alkyl group or a group -OR11, R11 representing a hydrogen or an aryl, heterocycloalkyl or heteroaryl group as defined below or an alkyl group, substituted or unsubstituted by a cycloalkyl, heterocycloalkyl, aryl or heteroaryl group as defined below;
- substituents of group 1 are chosen from -COOR12 and -CONR12R13;
- substituents of group 2 are chosen from -SO3H and -SO 2 NRI 2R13;
- R12 and R13 identical or different, representing a hydrogen or an unsubstituted alkyl radical; their stereoisomers (diastereoisomers, enantiomers), pure or in mixture, racemic mixtures, geometrical isomers, tautomers, salts, hydrates, solvates, solid forms as well as their mixtures.
- stereoisomers diastereoisomers, enantiomers
- alkyl denotes a saturated, linear, branched, halogenated or non-halogenated hydrocarbon-based radical, having more particularly from 1 to 24 carbon atoms, preferably from 1 to 10, and more particularly having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms. Mention may be made, for example, of methyl, trifluoromethyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, pentyl, neopentyl or n-hexyl radicals.
- cycloalkyl denotes an alkyl group as defined above and forming at least one ring. Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl may be mentioned as cycloalkyl groups having from 3 to 8 carbon atoms.
- heterocycloalkyl denotes a saturated or unsaturated alkyl group forming at least one ring interrupted by one or more heteroatoms chosen from N, O, S or P. Mention may be made, as heterocycloalkyl groups, of aziridine, pyrrolidine, tetrahydrothiophene, imidazoline, piperidine, piperazine and morpholine.
- aryl refers to aromatic groups preferably comprising 5 to 14 carbon atoms, advantageously 6 to 14 carbon atoms (ie 6, 7, 8, 9, 10, 11, 12, 13 or 14 carbon atoms); carbon). They are usually mono- or bi-cyclic. Mention may be made, for example, of phenyl, benzyl, ⁇ -naphthyl, ⁇ -naphthyl, anthracenyl or fluorenyl. In the context of the present invention, the aryl groups may be substituted with one or more substituents, which may be identical or different.
- halogens alkyl groups (as defined above) and alkyloxy (defined as an alkyl chain (as defined above) bound to the molecule. through an oxygen (ether linkage) alkylthio groups (defined as an alkyl chain (as defined above) linked to the molecule via a sulfur (thioether bond)) such as methyl, trifluoromethyl, methoxy and trifluoromethoxy, methylthio and trifluoromethylthio, amines, nitro groups, hydroxy groups, aryl, heteroaryl and heterocycle groups.
- heteroaryl refers to aromatic groups preferably comprising 3 to 14 carbon atoms, advantageously 3 to 8 carbon atoms (ie 3, 4, 6, 7 or 8 carbon atoms), interrupted by one or more heteroatoms chosen from N, O, S or P.
- heteroaryl groups having from 3 to 8 carbon atoms pyrrole, imidazole and pyridine may be mentioned.
- substituents of the heteroaryl groups there may be mentioned by way of example, halogens, alkyl groups (as defined above) and alkyloxy (defined as an alkyl chain (as defined above) bound to the molecule. via an oxygen (ether linkage) the alkylthio groups (defined as an alkyl chain (as defined above) bound to the molecule via a sulfur (thioether bond)).
- substituents are methyl, trifluoromethyl, methoxy and trifluoromethoxy, methylthio and trifluoromethylthio, amines, nitro groups, hydroxy groups, aryl, heteroaryl and heterocycle groups.
- the halogen atoms are chosen from bromine, fluorine, iodine and chlorine atoms.
- the atoms of the ring II are numbered from the atom X2, which bears the number 1, the other atoms of the ring being numbered from the carbon of the ring II related to the grouping AB.
- the ring II carbon attached to the AB group is carbon 2 (or C 2 )
- the carbon adjacent to C 2 is carbon 3 (or C 3 ), and so on.
- a particular aspect of the invention relates to the compounds of general formula (I) wherein A represents a carbonyl group (CO).
- R11 representing an alkyl group, branched or linear, especially an alkyl group having 1 to 7 carbon atoms, substituted or unsubstituted by a cycloalkyl, heterocycloalkyl, aryl or heteroaryl group.
- R11 represents a methyl group.
- R 11 is an alkyl group having 1 to 7 carbon atoms substituted by an aryl group, in particular a phenyl group. Particularly preferably, R 11 is a methyl group substituted by a phenyl group, in other words R 11 is a benzyl group.
- A represents a group -CR9R10, R9 representing a hydrogen and R10 representing a hydroxyl group, an alkyl group or a group -OR11, R11 representing a grouping.
- alkyl substituted or unsubstituted with a cycloalkyl, heterocycloalkyl, aryl or heteroaryl group.
- Said alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl groups are optionally halogenated.
- R 11 represents a linear or branched alkyl group having 1 to 7 carbon atoms, preferably 1, 2, 3 or 4 carbon atoms, preferably 1 or 2 carbon atoms, advantageously R 11 represents the methyl group or ethyl.
- R11 may also be isopropyl.
- R11 is substituted by a cycloalkyl group, in particular cyclohexyl, an aryl group, in particular phenyl, a heterocyclic or heteroaryl group, in particular pyridinyl, said cycloalkyl, aryl, heterocyclic or heteroaryl groups being optionally halogenated.
- R 11 represents an alkyl group, preferably comprising a carbon, substituted by a phenyl, iodophenyl, cyclohexyl, or pyridinyl group.
- Another particular aspect of the invention relates to the compounds of general formula (I) in which A represents a group -CR9R10, R9 representing a hydrogen and R10 representing a hydroxyl group.
- a particular aspect of the invention relates to the compounds of general formula (I) wherein B represents a saturated, unsubstituted alkyl group comprising two carbon atoms (CH 2 -CH 2).
- Another particular aspect of the invention relates to the compounds of general formula (I) in which X5 represents a group R5, -OR5 or -SR5, R5 representing an alkyl group substituted by a substituent of group 1.
- X5 represents a group -OR5 in which R5 represents an alkyl group substituted with a substituent of group 1.
- R5 represents an alkyl group substituted with a substituent of group 1.
- the substituent of group 1 is -COOR12.
- R5 represents an alkyl radical formed of a linear and saturated carbon chain having 1 to 4 carbon atoms, said chain being linked at its end opposite to the phenyl (III) group, to a substituent of group 1.
- Said chain may be branched with at least one alkyl or alkenyl group having 1 to 4 carbon atoms, or substituted with a phenyl group.
- R12 and R13 which may be identical or different, represent a hydrogen or an alkyl radical having 1 to 4 carbon atoms.
- the substituent of group 1 is of the type -COOR12, R12 being as defined above and preferably representing a hydrogen or an alkyl group comprising 1, 2, 3, 4, 5 or 6 carbon atoms, preferably comprising 1 , 2, 3 or 4 carbon atoms, in particular a tert-butyl group.
- X5 is selected from the groups: -OC (CH) 2 COOR 2, -OCH (CH 2 CH 3) COOR ⁇ ,
- R 12 may especially be chosen from hydrogen and -CH 3 groups, -C (CH 3 ) 3 and -CH 2 CH 3 .
- X5 represents a group -OC (CH 3 ) 2 COOH, -OC (CH 3 ) 2 COOC (CH 3 ) 3 , -OCH (CH 2 CH 3 ) COOC (CH 3 ) 3 , -OCH (CH 2 CH 3) COOH, -OCH 2 COOH, -OCH 2 COOC (CH S) 3,
- a particular aspect of the invention relates to the compounds of general formula (I) in which X 8 represents a hydrogen atom.
- the compounds of general formula (I) have at least one of the groups X 3, X 4, X 6 and X 7 denoting a halogen atom or an alkyl group having 1 to 4 carbon atoms, preferably a halogen.
- Another particular object of the invention relates to the compounds of general formula (I) in which X3 and / or X4, which are identical or different, represent a halogen, preferably chlorine or fluorine.
- X 3 and X 4 are identical and represent a halogen, preferably a chlorine or fluorine atom, more preferably chlorine.
- Another particular object of the invention relates to the compounds of general formula (I) in which X 3 represents a hydrogen atom and X 4 represents a bromine or fluorine atom.
- the compounds of general formula (I) have at least one of the groups X 3, X 4, X 6 and X 7 denoting a halogen atom or an alkyl group having 1 to 4 carbon atoms and s) remaining group (s) (i.e. the non-halogenated or non-alkylated group (s) chosen from X3, X4, X6 and X7) denote (s) atom (s) of hydrogen.
- Another particular object of the invention relates to the compounds of formula (I) in which X4 and / or X6 denotes an alkyl group, in particular compounds in which X4 and X6 are two methyl groups, and X3 and X7 are hydrogen atoms.
- Another particular object of the invention relates to the compounds of general formula (I) in which X6 and X7 represent a hydrogen atom.
- X6 and X7 represent hydrogen and X3 and / or X4, which may be identical or different, represent a halogen, preferably chlorine or fluorine.
- X 1 represents a group R 1 or -OR 1
- R 1 representing a hydrogen or an alkyl group.
- R 1 represents an alkyl group containing 1, 2 or 3 carbon atoms, more preferably the alkyl group is halogen.
- X 1 is chosen from a trifluoromethyl group, a bromine atom, a methyloxy group, a methylthio group, a trifluoromethoxy group and a hydrogen atom.
- X1 represents a group -CF 3 , -OCF 3 , -SCH 3 .
- Another preferred aspect relates to the compounds of general formula (I) in which X 1 represents a halogen, preferably a bromine.
- Another particular object of the invention relates to the compounds of general formula (I) in which X 2 represents a sulfur atom.
- Another particular object of the invention relates to the compounds of general formula (I) in which ring II is substituted by ring I in position C 4 .
- Another particular object of the invention relates to the compounds of general formula (I) in which ring II is substituted by ring I in position C 5 .
- Another particular object of the invention relates to the compounds of general formula (I) in which ring I is substituted by group X1 in position C 3 (or in meta with respect to ring II)
- Another particular object of the invention relates to the compounds of general formula (I) in which the ring I is substituted by the group X1 in position C 4 (or in para with respect to ring II).
- R 1 represents a hydrogen or an alkyl group having 1 to 4 carbon atoms, said alkyl group possibly being halogenous and R 3, R 4, R 6, R 7 and R8, which may be identical or different, are chosen from a hydrogen or an alkyl group having 1 to 4 carbon atoms.
- the subject of the invention is the compounds of general formula (I) in which at least one of the following conditions, preferably all the conditions, is fulfilled:
- X6 and X7 identical represent a hydrogen; and or
- X3 and / or X4 which may be identical or different, represent a halogen, preferably chlorine or fluorine; and or
- X 2 represents oxygen or sulfur, preferably sulfur;
- X5 represents a group R5, -OR5 or -SR5, where R5 represents an alkyl group substituted with a substituent of group 1; and / or ring II is substituted by ring I at C 4 or C 5 . ; and / or the ring I is substituted by the group X1 in position C 3 or in position C 4 ; and or
- X1 represents a halogen, a group R1, -SR1 or -OR1, R1 representing a hydrogen or an alkyl group; and or
- A represents:
- R11 representing a hydrogen or an aryl, heterocycloalkyl, or heteroaryl group as defined below or an alkyl group, substituted or unsubstituted by a cycloalkyl, heterocycloalkyl, aryl or heteroaryl group as defined above; and or
- B represents a saturated, unsubstituted alkyl group comprising two carbon atoms (CH 2 -CH 2 ).
- the subject of the invention is compounds derived from substituted 3-phenyl-1- (phenylthienyl) propan-1-one and 3-phenyl-1- (phenylfuranyl) propan-1-one compounds.
- X1 represents a halogen, a group R1, -SR1 or -OR1
- X2 represents a sulfur or oxygen atom
- X3 represents a halogen, a group R3, -SR3 or -OR3
- X4 represents a halogen, a group R4, -SR4 or -OR4
- X5 represents a group R5, -SR5 or -OR5
- X6 represents a halogen, a group R6, -SR6 or -OR6
- X7 represents a halogen, a group R7, -SR7 or -OR7
- X8 represents a group R8
- R 1 representing a hydrogen or an alkyl group having 1 to 4 carbon atoms, said alkyl group possibly being halogen
- R 1 representing a hydrogen or an alkyl group having 1 to 4 carbon atoms, said alkyl group possibly being halogen
- R3, R4, R6, R7 and R8, which are identical or different, chosen from a hydrogen or an alkyl group having 1 to 4 carbon atoms;
- R5 represents an alkyl radical formed of a linear and saturated carbon chain, having 1 to 4 carbon atoms, preferably 1 carbon atom, said carbon chain being:
- A represents:
- R9 representing a hydrogen atom
- R10 representing a group -OR11
- R11 being chosen from a hydrogen atom, an alkyl group (linear or branched) having 1 to 7 carbon atoms, preferably having 1, 2 or 3 carbon atoms, said alkyl group being substituted or unsubstituted by a cycloalkyl group, in particular cyclohexyl, an aryl group, in particular phenyl, or a heteroaryl group, in particular pyridinyl, said alkyl, cycloalkyl, aryl or heteroaryl being optionally halogenated,
- A represents a group -CHOR 11, R 11 being preferably chosen from a hydrogen atom, a methyl, ethyl or isopropyl group. cyclohexylmethyl, benzyl, iodobenzyl and pyridinylmethoxyl.
- the particularly preferred embodiment of the invention relates to compounds of general formula (I) in which X5 is a group -OR5, or a bioisomer of the group -OR5, in particular a group -SR5, with R5 denoting an alkyl radical of which said carbon chain is bonded to a substituent -COOR12.
- X 5 is chosen from the groups: -OC (CH 3 ) 2 COOR 12, -OCH (CH 2 CH 3 ) COORI 2, -O (CH 2 ) 3 C (CH 3 ) 2 COOR 12, - OCH (C 6 H 5 ) COORI 2 and -OCH 2 COORI 2.
- R12 is chosen from hydrogen and the groups - CH 3 , -C (CH 3 ) 3 and -CH 2 CH 3 .
- X 8 denotes a hydrogen atom.
- a particular object of the invention concerns, in the particularly preferred embodiment of the invention, the compounds of general formula (I) in which ring II is substituted by ring I in position C 4 .
- Another particular object of the invention relates, in the particularly preferred embodiment of the invention, to the compounds of general formula (I) in which ring II is substituted by ring I in position C 5 .
- the group X1 can be in any position of the cycle I, that is to say in the ortho, meta or para position with respect to the cycle II.
- X1 is in the meta or para position, preferably in the para position, with respect to cycle II.
- X 1 is chosen from a trifluoromethyl group, a bromine atom, a methyloxy group, a methylthio group, a trifluoromethoxy group and a hydrogen atom. hydrogen.
- the compounds according to the invention have at least one of the groups X 3, X 4, X 6 and X 7 denoting a halogen atom or an alkyl group having 1 to 4 carbon atoms.
- the remaining group (s) designate, hydrogen atom (s)
- they may also be compounds for which X 3 and X 4 are identical and correspond to halogen atoms (chlorine, fluorine, bromine or iodine), especially chlorine or fluorine.
- They may also be compounds for which X4 and / or X6 denotes an alkyl group, in particular compounds for which X4 and X6 are two methyl groups, and X3 and X7 are hydrogen atoms.
- X 4 and / or X 6 denotes an alkyl group, in particular X 4 and X 6 are two methyl groups, and X 3 and X 7 are atomic groups. 'hydrogen.
- the compounds according to the invention are chosen from:
- the compounds according to the invention may contain one or more asymmetric centers.
- the present invention includes stereoisomers (diastereoisomers, enantiomers), pure or in mixture, as well as racemic mixtures and geometric isomers.
- an enantiomerically pure (or enriched) mixture is desired, it may be obtained either by purification of the final product or chiral intermediates, or by asymmetric synthesis according to methods known to those skilled in the art (using, for example, reagents and catalysts chiral).
- Some compounds according to the invention may have different stable tautomeric forms and all such forms and mixtures thereof are included in the invention.
- the present invention also relates to the "pharmaceutically acceptable" salts of the compounds according to the invention.
- this term refers to the low or non-toxic salts obtained from bases or acids, organic or inorganic. These salts can be obtained during the final purification step of the compound according to the invention or by incorporation of the salt on the already purified compound.
- Certain compounds according to the invention and their salts could be stable in several solid forms.
- the present invention includes all forms solids of the compounds according to the invention, which includes amorphous, polymorphic, mono- and polycrystalline forms.
- the compounds according to the invention may exist in free form or in solvated form, for example with pharmaceutically acceptable solvents such as water (hydrates) or ethanol.
- the compounds according to the invention labeled with one or more isotopes are also included in the invention: these compounds are structurally identical but differ in that at least one atom of the structure is replaced by an isotope (radioactive or not).
- isotopes that can be included in the structure of compounds according to the invention may be selected from hydrogen, carbon, oxygen, sulfur such as 2 H, 3 H, 13 C, 14 C, 18 O , 17 O, 35 S respectively.
- the 3 H and 14 C radioactive isotopes are particularly preferred because they are easy to prepare and detect in vivo in vivo bioavailability studies.
- the heavy isotopes (such as H 2) are preferred because they are used as internal standards in analytical studies.
- the subject of the present invention is also the process for the synthesis of the compounds of general formula (I), which comprises:
- Y5 represents a group R5, -SR5, -OR5, hydroxy or thiol, R5 being as defined above; 2. optionally a step of reducing the compounds obtained in step
- step (1) in acidic or basic medium and step (2) are known to those skilled in the art and can vary to a large extent.
- the synthesis protocols can be in particular those presented in the "examples" part of the present invention.
- the bringing into contact of these two compounds is advantageously performed stoichiometrically. It is preferably carried out at a suitable temperature (between about 18 ° C. and 100 ° C.) and preferably at atmospheric pressure.
- the reaction is preferably carried out in the presence of a strong base, such as an alkali metal hydroxide, such as sodium hydroxide or an alkali metal alcoholate such as sodium ethoxide.
- a strong base such as an alkali metal hydroxide, such as sodium hydroxide or an alkali metal alcoholate such as sodium ethoxide.
- reaction is preferably carried out in the presence of a strong acid, such as hydrochloric acid.
- the subject of the present invention is also the compounds as described above, as medicaments.
- the present invention also relates to a compound as described above, for the treatment of complications associated with the metabolic syndrome, atherosclerosis, cerebral ischemia, autoimmune diseases, cardiovascular diseases, insulin-dependent resistance, obesity, hypertension, diabetes, dyslipidemia, inflammatory diseases (such as asthma), neurodegenerative particularly multiple sclerosis, Parkinson's disease, Alzheimer's disease, tauopathies (frontotemporal dementia, Pick's disease, cortico-basal degeneration, progressive supranuclear palsy), cortical dementia, spinal amyotrophy, cognitive disorders (MCI: MiId Cognitive Impairment), synucleopathies, Lewy body diseases, Huntington's chorea, epilepsy, amyotrophic lateral sclerosis, prion diseases (Creutzfeld-Jakob Disease), Down syndrome, Friedreich's Ataxia, spino-cerebellar ataxias, Charcot-Marie-Tooth's disease, neurological complications associated with AIDS, chronic pain, cerebellar degeneration, cerebellar hypoxia, neuropathies associated
- the subject of the invention is a compound as described above for treating cardiovascular risk factors related to disorders of lipid and / or carbohydrate metabolism, in particular hyperlipidemias and obesity, and in particular diabetes (diabetes type II).
- the invention relates to a compound as described above, for the treatment of dyslipidemias.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising, in a pharmaceutically acceptable carrier, at least one compound as described above, optionally in combination with one or more other therapeutic and / or cosmetic active ingredients.
- a pharmaceutical composition for the treatment of complications associated with the metabolic syndrome atherosclerosis, cerebral ischemia, autoimmune diseases, cardiovascular diseases, insulin resistance, obesity , hypertension, diabetes, dyslipidemia, inflammatory diseases (such as asthma), neurodegenerative diseases (especially multiple sclerosis, Parkinson's disease, Alzheimer's disease, tauopathies (frontotemporal dementia, Pick's disease, cortico-basal degeneration, progressive supranuclear palsy), cortical dementia, spinal amyotrophy, mild cognitive impairment (MCI: MiId Cognitive Impairment), synucleopathies, Lewy body disorders, Huntington's disease, epilepsy, amyotrophic lateral sclerosis, prion diseases (Creutzfeld-Jakob disease), Down's syndrome, Friedreich's ataxia, spino-cerebellar ataxias, Charcot-Marie- Tooth, neurological complications associated with AIDS, chronic pain, cerebellar degeneration, cerebellar hypoxia, neuropathies associated with diabetes), cancers, etc
- It is preferably a pharmaceutical composition for treating cardiovascular risk factors related to disorders of lipid and / or carbohydrate metabolism, in particular hyperlipidemias and obesity, and in particular diabetes (type II diabetes).
- the pharmaceutical composition according to the invention is intended for the treatment of dyslipidemias.
- Another subject of the invention relates to a nutritional composition
- a nutritional composition comprising at least one compound as described above.
- the subject of the present invention is also the compounds as described above, as cosmetic products.
- Another subject of the invention resides in the use of at least one compound as described above for the preparation of pharmaceutical compositions intended for the treatment of various pathologies as defined above, in particular related to metabolic disorders. lipids and / or carbohydrates among which may be mentioned dyslipidemias. More generally, the subject of the invention is the use of at least one compound as described above for the preparation of pharmaceutical compositions intended to treat the risk factors for cardiovascular diseases linked to disorders of the metabolism of lipids and / or carbohydrates and intended to reduce overall cardiovascular risk.
- the compounds according to the invention may advantageously be administered in combination with one or more other therapeutic and / or cosmetic agents, commercialized or in development, such as:
- insulinosecretors sulfonylureas (glibenclamide, glimepiride, gliclazide, etc.) and glinides (repaglinide, nateglinide, etc.)
- alpha-glucosidase inhibitors PPAR ⁇ agonists (thiazolidinediones such as rosiglitazone, pioglitazone), mixed agonists PPAR ⁇ / PPAR ⁇ (tesaglitazar, muraglitazar), pan-PPAR (compounds simultaneously activating the 3 PPAR isoforms), biguanides (metformin), dipeptidyl peptidase IV inhibitors (sitagliptin, vildagliptin), agonists Glucagon-Like Peptide-1 (GLP-1) (exenatide), etc.
- PPAR ⁇ agonists thiazolidinediones such as rosiglitazone, pioglitazone
- hypolipidemic and / or hypocholesterolemic molecules fibrates (fenofibrate, gemfibrozil), HMG CoA reductase inhibitors or hydroxylmethylglutaryl Coenzyme A reductase inhibitors (statins such as atorvastatin, simvastatin, fluvastatin), cholesterol absorption inhibitors ( ezetimibe, phytosterols), inhibitors of CETP or Cholesteryl Ester Transfer Protein (torcetrapib), ACAT inhibitors or Acyl-Coenzyme A cholesterol acylTransferase (Avasimibe, Eflucimibe), MTP (Microsomal Triglyceride Transfer Protein) inhibitors, agents sequestrants of bile acids (cholestyramine), vitamin E, polyunsaturated fatty acids, omega 3 fatty acids, nicotinic acid derivatives (niacin), etc.
- fibrates fibrates
- angiotensin-converting enzyme (ACE) inhibitors captopril, enalapril, ramipril or quinapril
- angiotensin II receptor antagonists leukin, renin, renin, renin, renin, renin, renin, renin, renin, renin, renin, renin, renin, renin, renin, renin, renin II receptor antagonists (losartan, valsartan, telmisartan, eposartan, irbesartan, etc.), beta-blockers (atenolol, metoprolol, labetalol, propranolol), thiazide diuretics and non-thiazides (furosemide, indapamide, hydrochlorothiazide, anti-aldosterone), vasodilators, calcium channel blockers (nifedipine, felodipine or aml
- anti-platelet agents Aspirin, Ticlopidine, Dipyhdamol, Clopidogrel, Flurbiprofen, etc.
- anti-obesity agents Sibutramine, lipase inhibitors (orlistat), PPAR ⁇ agonists and antagonists, cannabinoid CB1 receptor antagonists (rimonabant), etc.
- anti-inflammatory agents for example, corticosteroids (prednisone, betamethasone, dexamethasone, prednisolone, methylprednisolone, hydrocortisone, etc.), NSAIDs or non-steroidal anti-inflammatory drugs derived from indole (indomethacin, sulindac), NSAIDs from the arylcarboxylic group (tiaprofenic acid, diclofenac, etodolac, flurbiprofen, ibuprofen, ketoprofen, naproxen, nabumetone, alminoprofen), NSAIDs derived from oxicam (meloxicam, piroxicam, tenoxicam), NSAIDs from the fenamate group, selective inhibitors COX2 (celecoxib, rofecoxib), etc.
- corticosteroids prednisone, betamethasone, dexamethasone, predni
- anti-oxidizing agents for example probucol, etc.
- agents used in the treatment of heart failure thiazide or non-thiazide diuretics (furosemide, indapamide, hydrochlorothiazide, anti-aldosterone), ACE inhibitors (captopril, enalapril, ramipril or quinapril), digitalis ( digoxin, digitoxin), beta-blockers (atenolol, metoprolol, labetalol, propranolol), phosphodiesterase inhibitors (enoximone, milhnone), etc.
- beta-blockers atenolol, metoprolol, labetalol, propranolol
- calcium channel blockers nifedipine, felodipine or amlodipine, bepridil, diltiazem or verapamil
- the donor agents NO trinitrin, isosorbide dinitrate, molsidomine
- Amiodarone etc.
- anticancer agents cytotoxic agents (agents interacting with DNA, alkylating agents, cisplatin and derivatives), cytostatic agents (GnRH analogues (Gonatropin-Releasing Hormone), somatostatin analogues, progestins, anti-estrogens inhibitors aromatase, etc.), modulators of the immune response (interferons, IL2, etc.), etc.
- anti-asthmatics such as bronchodilators (beta2 receptor agonists), corticosteroids, cromoglycate, leukotriene receptor antagonists (montelukast), etc.
- corticosteroids used in the treatment of skin pathologies such as psoriasis and dermatitis
- vasodilators and / or anti-ischemic agents (buflomedil, Ginkgo Biloba extract, naftidrofuryl, pentoxifylline, piribedil), etc.
- the invention also relates to a method for treating various pathologies as defined above, particularly related to disorders of lipid metabolism and / or carbohydrates comprising the administration to a subject, in particular human, of an effective amount of a compound or a pharmaceutical composition as defined above.
- an effective amount refers to an amount of the compound sufficient to produce the desired biological result.
- subject refers to a mammal and more particularly a human.
- treatment refers to curative, symptomatic and / or preventive treatment.
- the compounds of the present invention can thus be used in subjects (such as mammals, in particular humans) with a declared disease.
- the compounds of the present invention can also be used to delay or slow progression or prevent further progression of the disease, thereby improving the condition of the subjects.
- the compounds of the present invention may finally be administered to non-diseased subjects who may develop the disease normally or who have a significant risk of developing the disease.
- compositions according to the invention advantageously comprise one or more excipients or vehicles, which are pharmaceutically acceptable.
- excipients or vehicles which are pharmaceutically acceptable.
- the compositions may contain one or more agents or vehicles selected from dispersants, solubilizers, stabilizers, preservatives, etc.
- Agents or vehicles that can be used in formulations include methylcellulose, hydroxymethylcellulose, carboxymethylcellulose, polysorbate 80, mannitol, gelatin, lactose, vegetable oils, and the like. acacia, liposomes, etc.
- compositions may be formulated as injectable suspensions, gels, oils, tablets, suppositories, powders, capsules, aerosols, etc., optionally using dosage forms or devices providing sustained and / or delayed release.
- an agent such as cellulose, carbonates or starches is advantageously used.
- the compounds or compositions according to the invention can be administered in different ways and in different forms. Thus, they may be, for example, administered systemically, orally, parenterally, by inhalation or by injection, for example intravenously, intramuscularly, subcutaneously, trans-dermally, intra-arterially, etc.
- the compounds are generally packaged as liquid suspensions, which can be injected by means of syringes or infusions, for example.
- the flow rate and / or the injected dose can be adapted by those skilled in the art depending on the patient, the pathology, the mode of administration, etc.
- the compounds are administered at doses ranging between 1 ⁇ g and 2 g per administration, preferably from 0.01 mg to 1 g per administration. Administrations can be daily or repeated several times a day, if necessary.
- the compositions according to the invention may comprise, in addition, other agents or active principles. LEGENDS OF FIGURES
- VLDL-Cholesterol Very-Low-Density-Lipoprotein Cholesterol
- FIGS. 1-1 to 1-9 In Vivo Evaluation, in the E2 / E2 Mouse, of the Lipophilic and Stimulating Properties of the Synthesis of HDL-Cholesterol of the Compounds According to the Invention by Lipid Assays and Measurement of the Expression of Engaged Gene in lipid and lipid metabolism and energy dissipation
- the lipid-lowering effect of the compounds according to the invention was evaluated in vivo in the E2 / E2 mouse (humanized for the E2 isoform of apolipoprotein E) by analyzing the distribution of cholesterol and triglycerides in the different fractions. plasma lipoproteins and by measuring plasma total cholesterol and HDL-cholesterol levels after 7 and 13 days of oral treatment; these levels are compared with those obtained with control animals (not treated with the compounds according to the invention). The difference measured shows the lipid-lowering effect of the compounds according to the invention.
- FIG. 1-4 distribution of triglycerides in the various plasma lipoprotein fractions after 13 days of treatment with compound 2, administered at 50 mpk.
- the effectiveness of the compounds according to the invention was also evaluated by measuring, in liver and muscle tissues (skeletal), the expression of genes involved in lipid metabolism, carbohydrate and energy dissipation. Expression levels of each gene were normalized to the level of expression of 36B4 reference genes in liver tissue or 18S in gastrocnemius skeletal muscle.
- the induction factor that is to say the ratio between the relative signal (induced by the compound according to the invention) and the average of the relative values of the control group was then calculated. The higher this factor, the more the compound has an activating character of gene expression. The final result is represented as the average of the induction values in each experimental group.
- FIG. 1 -5 expression of PDK4 (pyruvate dehydrogenase kinase, isoform 4) in the liver tissue, in E2 / E2 mice, after 13 days of treatment with compound 2 (50 mpk);
- PDK4 pyruvate dehydrogenase kinase, isoform 4
- FIG. 1 -6 Expression of Acoxi in liver tissue, in E2 / E2 mice, after 13 days of treatment with compound 2 (50 mpk);
- Figure 1-7 expression of ApoCIII in liver tissue, in E2 / E2 mice, after 13 days of treatment with compound 2 (50 mpk);
- FIG. 1 -8 expression of PDK4 (pyruvate dehydrogenase kinase, isoform 4) in skeletal muscle, in E2 / E2 mice, after 13 days of treatment with compound 2 (50 mpk);
- PDK4 pyruvate dehydrogenase kinase, isoform 4
- FIGS. 2-1 to 2-6 In Vivo Evaluation, in the C57BI6 Mouse, of the Lipid-lowering and Stimulating Properties of the Synthesis of HDL-Cholesterol of the Compounds According to the Invention by Lipid Assays and Measurement of the Expression of Genes Involved in the lipid metabolism, carbohydrate and energy dissipation.
- FIG. 2-1 total plasma cholesterol level after 14 days of treatment with compound 2 according to the invention, administered at 1, 5, 10 and 50 mpk, in C57BI6 mice;
- FIG. 2-2 plasma HDL-cholesterol level after 14 days of treatment with compound 2 according to the invention, administered at 1, 5, 10 and 50 mpk, in C57BL6 mice;
- FIG. 2-3 levels of plasma triglycerides after 14 days of treatment with compound 2 according to the invention, administered at 1, 5, 10 and 50 mpk, in C57BI6 mice;
- FIG. 2-4 Plasma free fatty acid levels after 14 days of treatment with compound 2 according to the invention, administered at 1, 5, 10 and 50 mpk, in C57BI6 mice.
- the effectiveness of the compounds according to the invention was also evaluated by measuring, in the muscular tissue (skeletal), the expression of genes involved in carbohydrate metabolism and energy dissipation. Expression levels of each gene were normalized to the level of expression of the 18S reference gene. The induction factor, was then calculated. The higher this factor, the more the compounds have an activating character of gene expression. The final result is represented as the average of the induction values in each experimental group.
- Figure 2-5 Expression of PDK4 in skeletal muscle, in C57BI6 mice, after 14 days of oral treatment with compound 2 (50 mpk);
- FIGS. 3-1 to 3-7 In Vivo Evaluation, in the C57BI6 Mouse, of the Stimulating Properties of the Synthesis of HDL-Cholesterol of the Compounds According to the Invention by Lipid Assays and Measurement of the Expression of the Genes Involved in Lipid Metabolism , carbohydrate and energy dissipation.
- the effect of the compounds according to the invention was evaluated in vivo in C57BI6 mice after 14 days of oral treatment. At the end of the treatment, the distribution of cholesterol in the different plasma lipoprotein fractions was determined. This was compared to the profile obtained for the control animals (not treated with the compounds according to the invention).
- the effect of the compounds according to the invention was also evaluated in vivo in C57BI6 mice by measuring the plasma levels of total cholesterol and HDL-cholesterol after 14 days of oral treatment. These levels were compared with those obtained for control animals (not treated with the compounds according to the invention). The difference measured shows the lipid-lowering effect of the compounds according to the invention.
- FIG. 3-1 total plasma cholesterol level after 14 days of treatment with compounds 4 and 7 according to the invention, administered at 50 mpk;
- FIG. 3-2 plasma HDL cholesterol level after 14 days of treatment with compounds 4 and 7 according to the invention, administered at 50 mpk;
- FIG. 3-3 distribution of cholesterol in the various plasma lipoprotein fractions after 14 days of treatment with compounds 4 and 7 according to the invention, administered at 50 mpk.
- the effectiveness of the compounds according to the invention was also evaluated by measuring, in the muscular tissue (skeletal), the expression of genes involved in lipid metabolism, carbohydrate and energy dissipation. Expression levels of each gene were normalized to the level of expression of the 18S reference gene. The induction factor was then calculated. The higher this factor, the more the compounds have an activating character of gene expression. The final result is represented as the average of the induction values in each experimental group. 3-4: expression of PDK4 in muscle tissue, in C57BI6 mice, after 14 days of treatment with compound 7 (50 mpk);
- Figure 3-5 expression of CPTI b in muscle tissue, in C57BI6 mice, after 14 days of treatment with compounds 4 and 7 (50 mpk);
- Figure 3-6 expression of UCP2 in muscle tissue, in C57BI6 mice, after 14 days of treatment with compounds 4 and 7 (50 mpk);
- FIG. 3-7 Expression of UCP3 in muscle tissue, in C57BI6 mice, after 14 days of treatment with compounds 4 and 7 (50 mpk).
- Figures 4-1 to 4-7 In vivo evaluation, in db / db mice, lipid-lowering, antidiabetic and PPAR-activating properties of the compounds according to the invention.
- the effect of the compounds according to the invention was evaluated in vivo in db / db mice by measuring plasma triglycerides and insulinemia after 28 days of oral treatment with compound 2. These levels were compared to those obtained with control animals (not treated with the compound according to the invention). The difference measured reflects the lipid-lowering effect and the insulin resistance of the compound according to the invention.
- FIG. 4-1 plasma triglyceride levels after 28 days of treatment with compound 2, administered at 50 mpk in the db / db mouse;
- FIG. 4-2 Plasma insulin level after 28 days of treatment with compound 2, administered at 50 mpk in db / db mice.
- the efficacy of compound 2 was also evaluated by measuring, in liver and muscle tissues, the expression of genes involved in carbohydrate, lipid metabolism, and energy dissipation. Expression levels of each gene were normalized to the level of expression of the reference genes 36B4 in the liver and 18S in skeletal muscle.
- the induction factor that is to say the ratio between the relative signal (induced by the compound according to the invention) and the average of the relative values of the control group, was then calculated. The higher this factor, the more the compound has an activating character of gene expression. The final result is represented as the average of the induction values in each experimental group.
- Figure 4-3 expression of PDK4 in liver tissue, in db / db mice, after 28 days of treatment with compound 2, administered at 50 mpk;
- Figure 4-4 expression of ACOXI in liver tissue, in db / db mice, after 28 days of treatment with compound 2, administered at 50 mpk;
- Figure 4-5 Expression of CPTI b in liver tissue, in db / db mice, after 28 days of treatment with compound 2, administered at 50 mpk;
- Figure 4-6 expression of PDK4 in muscle tissue, in db / db mice, after 28 days of treatment with compound 2, administered at 50 mpk;
- Figure 4-7 expression of UCP3 in muscle tissue, in db / db mice, after 28 days of treatment with compound 2, administered at 50 mpk.
- FIG. 5 In vitro evaluation of the metabolic properties of the compounds according to the invention by measuring the ⁇ -oxidation of fatty acids in murine mvocvtes
- the stimulatory effects of the compounds according to the invention were evaluated by measuring the ⁇ -oxidation of fatty acids in murine myocytes pretreated for 24 hours with the compounds according to the invention.
- Figures 6-1 and 6-2 In vitro evaluation of the properties activating the reverse transport of cholesterol compounds according to the invention by measuring the expression of the ABCA1 gene in macrophages.
- the effect of the compounds according to the invention on the reverse transport of cholesterol was evaluated by measuring the expression of the ABCA1 gene (ATP-binding cassette, sub-family A, member 1, membrane transporter involved in the efflux of cholesterol) in human macrophages. Plus the expression of ABCAl is increased, the compound according to the invention stimulates the reverse transport of cholesterol.
- ABCA1 gene ATP-binding cassette, sub-family A, member 1, membrane transporter involved in the efflux of cholesterol
- FIG. 6-1 expression of ABCA1 in human macrophages, after 24 hours of treatment with compound 2, at 1 ⁇ M;
- FIG. 6-2 expression of ABCA1 in human macrophages, after 24 hours of treatment with compounds 4 and 7 according to the invention, at 1 ⁇ M and 30 ⁇ M, respectively.
- FIGS. 7-1 to 7-4 In vitro evaluation of the anti-inflammatory properties of the compounds according to the invention by measuring the secretion and the expression of MCP1 and MMP9 by human monocytes treated with the compounds according to the invention and stimulated with PMA
- the anti-inflammatory effects of the compounds according to the invention were evaluated by measuring the secretion and the expression of the Monocyte Chemoattractant Protein-1 (MCP1) as well as by the measurement of the expression of the matrix metalloproteinase 9 ( MMP9) by human monocytes treated for 24 hours with the compounds according to the invention and stimulated with PMA (phorbol 12-myhstate 13-acetate, which causes an inflammatory response of the cells).
- MCP1 Monocyte Chemoattractant Protein-1
- MMP9 matrix metalloproteinase 9
- FIG. 7-1 secretion of MCP1 (Monocyte Chemoattractant Protein-1) in human monocytes treated with compounds 7 and 11 according to the invention at 1 ⁇ M;
- MCP1 Monocyte Chemoattractant Protein-1
- FIG. 7-2 expression of MCP1 (Monocyte Chemoattractant Protein-1) in human monocytes treated with compounds 7 and 11 according to the invention at 1 ⁇ M;
- FIG. 7-3 expression of MMP9 (matrix metalloproteinase 9) in human monocytes treated with compounds 7 and 11 according to the invention at 1 ⁇ M;
- FIG. 7-4 expression of MCP1 (Monocyte Chemoattractant Protein-1) in human monocytes, treated with compound 2 at 0.1 and 0.3 ⁇ M.
- MCP1 Monocyte Chemoattractant Protein-1
- the statistical studies performed consist of a Student's T test and / or Univariate One-way Variance Analysis (ANOVA), followed by a Tukey test. The results are compared with the control group according to the value of the parameter p:
- the mass spectra are made by ESI-MS (Electrospray Ionisation - Mass).
- s for singlet if for singlet wide, d for doublet, dd for doublet split, ddd for double doublet split, t for triplet, td for split triplet, q for quadruplet, quintuplet for quintuplet, sext for sextuplet, m for multiplet or solid.
- the brominated derivative (0.5 to 75 g, 0.05 to 0.5 mol / mL), potassium carbonate (3 eq.) And water (11 eq.) are solubilized in N, N-dimethylformamide. under an inert atmosphere. Palladium acetate (0.1 eq) is added, and then the boronic acid solution in N, N-dimethylformamide (1.5 eq., 0.25 g / mL) is added dropwise. The medium is stirred, under an inert atmosphere at room temperature.
- the ketone (1 eq.) And the aldehyde (1 eq.) are solubilized in a solution of ethanol saturated with gaseous hydrochloric acid (0.2 g to 38 g, 0.2 to 0.5 mol / l) . After stirring for 16 hours at room temperature, the solvent is removed by evaporation under reduced pressure.
- Propenone is solubilized in a 2: 1 mixture of chloroform / methanol (0.2 to
- the tert-butyl ester is solubilized in dichloromethane (0.2 to 15 g, 0.1 to 1 mol / l) and then the trifluoroacetic acid (10 to 17 eq.) Is added. Stirring is maintained at room temperature.
- the ester is solubilized in ethanol (0.2 to 0.4 g, 0.1 to 0.2 mol / l) and then a 2N sodium hydroxide solution is added.
- Propanone is solubilized in ethanol (0.2 to 4 g, 0.1 to 0.5 mol / L).
- Sodium borohydride (3 eq) is added. The whole is kept stirring for 3 hours at room temperature. The solvent is removed by evaporation under reduced pressure, the evaporation residue is taken up in a dilute aqueous solution of hydrochloric acid and extracted with dichloromethane.
- the alcohol is solubilized in N, N-dimethylformamide (0.2 to 3 g, 0.1 to 0.5 mol / l), the solution is cooled to 0 ° C. and sodium hydride is then added. After stirring for 20 minutes, the appropriate alkyl halide is added. The medium is left stirring for 4 hours at room temperature. The solvents are removed by evaporation under reduced pressure.
- reaction medium After stirring for 1 hour, the reaction medium is diluted with water, filtered through Celite and then extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then concentrated under reduced pressure. The evaporation residue is recrystallized from cyclohexane.
- reaction medium After stirring for 12 hours, the reaction medium is diluted with water, filtered through celite and then extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then concentrated under reduced pressure. The evaporation residue is purified by chromatography on silica gel. Elution: cyclohexane / ethyl acetate: 9/1 to 8/2. 40-63 ⁇ m silica.
- 2-Acetylfuran is solubilized in N, N-dimethylformamide (5 g, 1.1 mol / L) and N-bromosuccinimide (1 eq) is added.
- reaction medium After stirring for 18 hours, the reaction medium is diluted with water and then extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then concentrated under reduced pressure. The evaporation residue is purified by chromatography on silica gel.
- reaction medium After stirring for 18 hours at 100 ° C., the reaction medium is diluted with water, filtered through celite and then extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then concentrated under reduced pressure.
- the evaporation residue is purified by chromatography on silica gel.
- the catalyst After stirring for 1 hour at 42 ° C., the catalyst is removed by filtration and the solvent is removed by evaporation under reduced pressure. The evaporation residue is purified by chromatography on silica gel.
- the catalyst is removed by filtration and the solvent is removed by evaporation under reduced pressure.
- the evaporation residue is purified by chromatography on silica gel.
- 3- (3-Chloro-4-hydroxyphenyl) -1- (5- (4- (thfluoromethyl) phenyl) thien-2-yl) prop-2-en-1-one is prepared from 1 - (5 - (4- (thfluoromethyl) phenyl) thien-2-yl) ethanone and 3-chloro-4-hydroxybenzaldehyde according to general procedure B.
- the evaporation residue is purified by chromatography on silica gel. Elution: cyclohexane / ethyl acetate: 6/4. 40-63 ⁇ m silica.
- 3- (3-Chloro-4-hydroxyphenyl) -1- (5- (4- (thfluoromethyl) phenyl) thien-2-yl) propan-1-one is prepared from 3- (3-chloro) 4-hydroxyphenyl) -1- (5- (4- (thfluoromethyl) phenyl) thien-2-yl) prop-2-en-1-one according to general procedure C. After stirring for 3 hours at room temperature, The catalyst is removed by filtration and the solvent is removed by evaporation under reduced pressure. The evaporation residue is purified by chromatography on silica gel. Elution: methylene chloride. 40-63 ⁇ m silica.
- 3- (3-Fluoro-4-hydroxyphenyl) -1- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) prop-2-en-1-one is prepared from 1 - (5 - (4- (trifluoromethyl) phenyl) thien-2-yl) ethanone and 3-fluoro-4-hydroxybenzaldehyde according to general procedure B. The residue is crystallized from acetonitrile.
- the catalyst is removed by filtration and the solvent is removed by evaporation under reduced pressure.
- the evaporation residue is purified by chromatography on silica gel.
- 3- (3-Bromo-4-hydroxyphenyl) -1- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) prop-2-en-1-one is prepared from 1 - (5 - (4- (trifluoromethyl) phenyl) thien-2-yl) ethanone and 3-bromo-4-hydroxybenzaldehyde according to general procedure B.
- the evaporation residue is crystallized from ethanol.
- the catalyst After stirring for 4 hours at room temperature, the catalyst is removed by filtration, the solvent is removed by evaporation under reduced pressure, the evaporation residue is purified by chromatography on silica gel.
- the catalyst After stirring for 24 hours at 40 ° C. under 5 bar of hydrogen pressure, the catalyst is removed by filtration and the solvents are removed by evaporation under reduced pressure. The evaporation residue is purified by chromatography on silica gel.
- the catalyst After stirring for 24 hours at room temperature under 10 bar of hydrogen pressure, the catalyst is removed by filtration and the solvents are removed by evaporation under reduced pressure. The evaporation residue is purified by chromatography on silica gel.
- the catalyst After stirring for 1 hour at 45 ° C., the catalyst is removed by filtration and the solvents are removed by evaporation under reduced pressure. The evaporation residue is purified by chromatography on silica gel.
- the catalyst After stirring for 24 hours at 50 ° C. under 10 bar of hydrogen pressure, the catalyst is removed by filtration and the solvent is removed by evaporation under reduced pressure. The evaporation residue is purified by chromatography on silica gel.
- the catalyst After stirring for 24 hours at 40 ° C. under 10 bar of hydrogen pressure, the catalyst is removed by filtration and the solvent is removed by evaporation under reduced pressure. The evaporation residue is purified by chromatography on silica gel.
- 3- (4-hydroxy-3-methylphenyl) -1- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) prop-2-en-1-one is prepared from 1 - (5 - (4- (thfluoromethyl) phenyl) thien-2-yl) ethanone and 4-hydroxy-3-methylbenzaldehyde according to general procedure B. The evaporation residue is washed with dichloromethane.
- the catalyst After stirring for 40 hours at 40 ° C. under 5 bar of hydrogen pressure, the catalyst is removed by filtration and the solvents are removed by evaporation under reduced pressure. The evaporation residue is purified by chromatography on silica gel.
- 3- (4-Hydroxyphenyl) -1- (5- (4- (thfluoromethyl) phenyl) thien-2-yl) propan-1-one is prepared from 3- (4-hydroxyphenyl) -1- ( 5- (4- (trifluoromethyl) phenyl) thien-2-yl) prop-2-en-1-one according to general procedure C. After 1.5 hours stirring at room temperature, the catalyst is removed by filtration and the solvents are removed by evaporation under reduced pressure. The evaporation residue is purified by chromatography on silica gel. Elution: cyclohexane / ethyl acetate: 8/2. 40-63 ⁇ m silica.
- the catalyst is removed by filtration and the solvents are removed by evaporation under reduced pressure.
- the evaporation residue is purified by chromatography on silica gel. Elution: cyclohexane / ethyl acetate: 8/2. 40-63 ⁇ m silica.
- reaction medium is washed with water and the dichloromethane is removed by evaporation under reduced pressure.
- the evaporation residue is recrystallized from methylene chloride.
- the evaporation residue is purified by chromatography on silica gel.
- 2- (4- (3- (Benzyloxy) -3- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propyl) -2,3-dichlorophenoxy) -2-methylpropanoic acid is prepared from 2- (2,3-dichloro-4- (3-hydroxy-3- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) -2-methyl acid -propanoic acid by means of 2.2 equivalents of sodium hydride and 2.2 equivalents of benzyl bromide according to general procedure H.
- the evaporation residue is solubilized in ethanol in the presence of 2N sodium hydroxide (20 eq. .).
- the two enantiomers of compound 7 are separated by Chiralpak®AD-H chiral column semi-preparative HPLC (250 * 20mm, 5 ⁇ m, Chiral Technologies Europe) at room temperature. The elution is carried out in isocratic mode with an n-heptane-ethanol mobile phase (95-5) added with 0.1% trifluoroacetic acid at a flow rate of 18 ml / min.
- Tertiobutyl 2- (2,3-dichloro-4- (3-oxo-3- (5- (4- (thfluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) butanoate is prepared from 3- (2,3-dichloro-4-hydroxyphenyl) -1- (5- (4- (thfluoromethyl) phenyl) thien-2-yl) propan-1-one and tert-butyl 2-bromobutanoate according to general procedure D .
- Tertiobutyl 2- (2,3-dichloro-4- (3-oxo-3- (4- (4- (trifluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) -2-methylpropanoate is prepared from 3- (2,3-dichloro-4-hydroxyphenyl) -1- (4- (4- (trifluoromethyl) phenyl) thien-2-yl) propan-1-one and tert-butyl bromoisobutyrate according to general procedure D .
- Methyl 5- (2,3-dichloro-4- (3-oxo-3- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) -2,2-dimethylpentanoate is prepared from 3- (2,3-dichloro-4-hydroxyphenyl) -1- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propan-1-one and 5-iodo-2, Methyl 2-dimethylpentanoate according to General Procedure D.
- 5- (2,3-Dichloro-4- (3-oxo-3- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) -2,2-dimethylpentanoic acid is prepared from 5- (2,3-dichloro-4- (3-oxo-3- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) -2,2-dimethylpentanoate methylated according to the general procedure F using 10 equivalents of a 2N sodium hydroxide solution.
- the solvents are removed by evaporation under reduced pressure.
- the evaporation residue is taken up in a dilute solution of hydrochloric acid and then extracted with methylene chloride.
- the organic phase is dried over magnesium sulphate, filtered and then concentrated under reduced pressure.
- the evaporation residue is purified by chromatography on silica gel.
- Tertiobutyl 2- (2,3-dichloro-4- (3-oxo-3- (5- (4- (thfluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) -acetate is prepared from 3- (2,3 dichloro-4-hydroxyphenyl) -1- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propan-1-one and tert-butyl bromoacetate according to general procedure D.
- Ethyl 2- (2,3-dichloro-4- (3-oxo-3- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) -2-phenylacetate is prepared according to from 3- (2,3-dichloro-4-hydroxyphenyl) -1- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propan-1-one and ethyl 2-bromophenylacetate according to the general procedure D. After stirring for 16 hours, the medium is acidified with a dilute hydrochloric acid solution and then extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then concentrated under reduced pressure.
- Tertiobutyl 2- (2-chloro-4- (3-oxo-3- (5- (4- (thfluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) -2-methylpropanoate is prepared from 3- (3-Chloro-4-hydroxyphenyl) -1- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propan-1-one and tertiary butyl bromoisobutyrate according to general procedure D. After 2 hours stirring, the medium is acidified with a dilute solution of 1 N citric acid and then extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then concentrated under reduced pressure.
- reaction medium After 1 hour at room temperature, the reaction medium is washed with water and the dichloromethane is removed by evaporation under reduced pressure.
- the evaporation residue is crystallized from a mixture of methylene chloride and heptane: 5/5.
- Tertiobutyl 2- (3-chloro-4- (3-oxo-3- (5- (4- (thfluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) -2-methylpropanoate is prepared from 3- (2-Chloro-4-hydroxyphenyl) -1- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propan-1-one and tert-butyl bromoisobutyrate according to general procedure D. After stirring for 2 hours, the medium is acidified with a dilute solution of 1 N citric acid and then extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then concentrated under reduced pressure.
- reaction medium After 1 hour at room temperature, the reaction medium is washed with water and the dichloromethane is removed by evaporation under reduced pressure.
- the evaporation residue is crystallized from a mixture of methylene chloride and heptane: 5/5.
- Tertiobutyl 2- (2-fluoro-4- (3-oxo-3- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) -2-methylpropanoate is prepared from 3- (3-Fluoro-4-hydroxyphenyl) -1- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propan-1-one and tertiary butyl bromoisobutyrate according to general procedure D. After 16 hours stirring, the solvent is removed by evaporation under reduced pressure and the evaporation residue is taken up in dichloromethane.
- Tertiobutyl 2- (2-fluoro-4- (3-oxo-3- (5- (4- (thfluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) acetate is prepared from 3- ( 3-fluoro-4-hydroxyphenyl) -1- (5- (4- (thfluoromethyl) phenyl) thien-2-yl) propan-1-one and tert-butyl bromoacetate according to general procedure D.
- the evaporation residue is solubilized in ethanol in the presence of 2N sodium hydroxide (20 eq.). After stirring for 16 hours, the solvents are removed by evaporation under reduced pressure. The evaporation residue is acidified with a dilute solution of hydrochloric acid and then extracted with methylene chloride. The organic phase is dried over magnesium sulphate, filtered and then concentrated under reduced pressure. The evaporation residue is purified by chromatography on silica gel (preparative HPLC, lichrospher (Merck) RP18 12 ⁇ m 100A, column: 25 * 250 mm).
- Tertiobutyl 2- (2-fluoro-4- (3-oxo-3- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) butanoate is prepared from 3- (3-Fluoro-4-hydroxyphenyl) -1- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propan-1-one and tert-butyl 2-bromobutanoate according to general procedure D.
- the oil obtained is crystallized in dichloromethane.
- the evaporation residue is purified by chromatography on silica gel.
- Tertiobutyl 2- (2-bromo-4- (3-oxo-3- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) butanoate is prepared from 3- (3-Bromo-4-hydroxyphenyl) -1- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propan-1-one and tert-butyl 2-bromobutanoate according to general procedure D. After 2 hours stirring, the medium is acidified with a dilute solution of 1 N citric acid and then extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then concentrated under reduced pressure.
- the evaporation residue is purified by chromatography on silica gel (preparative HPLC, lichrospher (Merck) RP18 12 ⁇ m 100A, column: 25 * 250 mm). Elution: water gradient, methanol + 0.1% trifluoroacetic acid: 30/70 to 0/100.
- Tertiobutyl 2- (2-bromo-4- (3-oxo-3- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) -acetate is prepared from 3- (3-bromo-4-hydroxyphenyl) -1- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propan-1-one and tert-butyl bromoacetate according to general procedure D. After 12 hours of stirring, the medium is acidified with a dilute solution of 1 N citric acid and then extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then concentrated under reduced pressure.
- the evaporation residue is purified by chromatography on silica gel (preparative HPLC, lichrospher (Merck) RP18 12 ⁇ m 100A, column: 25 * 250 mm).
- Tertiobutyl 2- (2-bromo-4- (3-oxo-3- (5- (4- (thfluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) -2-methylpropanoate is prepared from 3- (3-bromo-4-hydroxyphenyl) -1- (5- (4- (thfluoromethyl) phenyl) thien-2-yl) propan-1-one and tert-butyl bromoisobutyrate according to general procedure D. After 2 hours stirring, the medium is acidified with a dilute solution of 1 N citric acid and then extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then concentrated under reduced pressure.
- Tertiobutyl 2- (2,3-dichloro-4- (3-oxo-3- (5- (4- (thfluoromethyl) phenyl) fur-2-yl) propyl) phenoxy) -2-methylpropanoate is prepared from 3- (2,3-dichloro-4-hydroxyphenyl) -1- (5- (4- (thfluoromethyl) phenyl) fur-2-yl) propan-1-one and tert-butyl bromoisobutyrate according to general procedure D. After stirring for 16 hours, the solvent is removed by evaporation under reduced pressure. The evaporation residue is taken up in ethyl acetate.
- reaction medium After stirring for 2 hours at room temperature, the reaction medium is washed with water and then the dichloromethane is removed by evaporation under reduced pressure. The evaporation residue is purified by chromatography on silica gel.
- the reaction medium is diluted with water, acidified with a 1N hydrochloric acid solution and extracted with ethyl acetate.
- the organic phase is concentrated under reduced pressure and then treated with a 2N sodium hydroxide solution and extracted with dichloromethane.
- the dichloromethane is removed by evaporation under reduced pressure and the evaporation residue purified by flash chromatography on silica gel.
- the two enantiomers of compound 39 are separated by Chiralpak®AD-H chiral column semi-preparative HPLC (250 * 20mm, 5 ⁇ m, Chiral Technologies Europe) at room temperature. The elution is carried out in isocratic mode with a n-heptane-ethanol mobile phase (87-13) at a flow rate of 12 ml / min.
- the two enantiomers of compound 40 are separated by Chiralpak®AD-H chiral column semi-preparative HPLC (250 * 20mm, 5 ⁇ m, Chiral Technologies Europe) at room temperature.
- the elution is carried out in isocratic mode with an n-heptane-ethanol mobile phase (93-7) supplemented with 0.1% trifluoroacetic acid at a flow rate of 16 to 18 ml / min.
- reaction medium After stirring for 20 minutes at 70 ° C., the reaction medium is brought to ambient temperature, treated with a 2N sodium hydroxide solution and then acidified with a 1N hydrochloric acid solution and extracted with ethyl acetate. . The organic phase is concentrated under reduced pressure and the evaporation residue purified by flash chromatography on silica gel.
- reaction medium After stirring for 18 hours at 70 ° C., the reaction medium is acidified with a 1N hydrochloric acid solution and extracted with ethyl acetate. The organic phase is concentrated under reduced pressure and the evaporation residue is purified by flash chromatography on silica gel.
- Tertiobutyl 2- (2,3-dichloro-4- (3-oxo-3- (5- (4- (thfluoromethoxy) phenyl) thien-2-yl) propyl) phenoxy) -2-methylpropanoate is prepared according to from 3- (2,3-dichloro-4-hydroxyphenyl) -1- (5- (4- (thfluoromethoxy) phenyl) thien-2-yl) propan-1-one and tert-butyl bromoisobutyrate according to the general procedure D. After stirring for 6 hours, the medium is diluted with saturated ammonium chloride solution and extracted with ethyl acetate.
- Tertiobutyl 2- (2,3-difluoro-4- (3-oxo-3- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) -2-methylpropanoate is prepared from 3- (2,3-difluoro-4-hydroxyphenyl) -1- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propan-1-one and tert-butyl bromoisobutyrate according to general procedure D .
- the medium is acidified with a dilute solution of 1 N citric acid and then extracted with dichloromethane.
- the organic phase is dried over magnesium sulphate, filtered and then concentrated under reduced pressure.
- the evaporation residue is purified by flash chromatography on silica gel. Elution: cyclohexane / ethyl acetate: 92/8. 40-63 ⁇ m silica.
- Tertiobutyl 2- (2,6-dimethyl-4- (3-oxo-3- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) -2-methylpropanoate is prepared according to from 3- (4-hydroxy-3,5-dimethylphenyl) -1- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propan-1-one according to general procedure D, by means of 15 equivalents of tert-butyl bromoisobutyrate and 15 equivalents of potassium carbonate added in portions of 3 equivalents during the reaction.
- the solvents are removed by evaporation under reduced pressure.
- the evaporation residue is taken up in ethyl acetate and washed with a saturated ammonium chloride solution.
- the evaporation residue is purified by flash chromatography on silica gel.
- 2-yl) propyl) phenoxy) -2-methylpropanoic acid is prepared from 2- (2,3-dichloro-4- (3-oxo-3- (5- (4- (thfluoromethyl) phenyl) thien -2-yl) propyl) phenoxy) -2-methylpropanoic acid and hydroxylamine hydrochloride according to the general procedure I.
- 2-yl) propyl) phenoxy) -2-methylpropanoic acid is prepared from 2- (2,3-dichloro-4- (3-oxo-3- (5- (4- (trifluoromethyl) phenyl) thien -2-yl) propyl) phenoxy) -2-methylpropanoic acid and O-methylhydroxylamine hydrochloride according to general procedure I.
- Tertiobutyl 2- (4- (3- (5- (4-bromophenyl) thien-2-yl) -3-oxopropyl) -2,3-dichlorophenoxy) -2-methylpropanoate is prepared from 1 - (5- (4-bromophenyl) thien-2-yl) -3- (2,3-dichloro-4-hydroxyphenyl) propan-1 -one according to general procedure D, using 4 equivalents of tert-butyl bromoisobutyrate and of 5 equivalents of potassium carbonate.
- the medium is diluted with a solution of saturated ammonium chloride and extracted with ethyl acetate.
- the organic phase is dried over magnesium sulphate, filtered and then concentrated under reduced pressure.
- the evaporation residue is purified by flash chromatography on silica gel.
- 2- (4- (3- (5- (4-bromophenyl) thien-2-yl) -3-oxopropyl) -2,3-dichlorophenoxy) -2-methylpropanoic acid is prepared from 2- (4 - Tert-butyl (3- (5- (4-bromophenyl) thien-2-yl) -3-oxopropyl) -2,3-dichlorophenoxy) -2-methylpropanoate according to general procedure E using 38 equivalents of trifluoroacetic acid . After stirring for 1 hour at ambient temperature, the solvents are removed by evaporation under reduced pressure. The evaporation residue is purified by chromatography on silica gel.
- Tertiobutyl 2- (2,3-dichloro-4- (3- (5- (4- (methylthio) phenyl) thien-2-yl) -3-oxopropyl) phenoxy) -2-methylpropanoate is prepared from 3- (2,3-dichloro-4-hydroxyphenyl) -1- (5- (4- (methylthio) phenyl) thien-2-yl) propan-1-one solubilized in tetrahydrofuran according to general procedure D. After stirring for 20 hours at 70 ° C., the medium is diluted with a solution of saturated ammonium chloride and extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then concentrated under reduced pressure. The evaporation residue is purified by flash chromatography on silica gel.
- reaction medium After stirring for 12 hours at 70 ° C., the reaction medium is diluted with water, acidified with a 0.5N hydrochloric acid solution and extracted with ethyl acetate. The organic phase is concentrated under reduced pressure. The evaporation residue purified by flash chromatography on silica gel.
- Tertiobutyl 2- (2,3-dichloro-4- (3-oxo-3- (5-phenylthien-2-yl) propyl) phenoxy) -2-methylpropanoate is prepared from 3- 3-dichloro-4-hydroxyphenyl) -1- (5-phenylthien-2-yl) propan-1-one solubilized in tetrahydrofuran according to general procedure D.
- the medium is diluted with a solution of saturated ammonium chloride and extracted with ethyl acetate.
- the organic phase is concentrated under reduced pressure.
- the evaporation residue is washed with cyclohexane.
- Tertiobutyl 2-methyl-2- (2-methyl-4- (3-oxo-3- (5- (4- (trifluoromethyl) phenyl) thien-2-yl) propyl) phenoxy) propanoate is prepared from 3- (4-hydroxy-3-methylphenyl) -1- (5- (4- (thfluoromethyl) phenyl) thien-2-yl) propan-1-one, solubilized in tetrahydrofuran, according to general procedure D.
- the medium After stirring for 12 hours at 70 ° C., the medium is diluted with a solution of saturated ammonium chloride and extracted with ethyl acetate. The organic phase is concentrated under reduced pressure. The evaporation residue purified by flash chromatography on silica gel.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES07872038.0T ES2544959T3 (es) | 2006-12-29 | 2007-12-28 | Derivados de 3-fenil-1-(feniltienil)propan-1-ona y de 3-fenil-1-(fenilfuranil)propan-1-ona sustituidos, preparación y utilización |
CN200780051301.5A CN101605775B (zh) | 2006-12-29 | 2007-12-28 | 取代的3-苯基-1-(苯基噻吩基)丙-1-酮类以及3-苯基-1-(苯基呋喃基)丙-1-酮类的衍生物、制备以及用途 |
KR1020097015966A KR101505577B1 (ko) | 2006-12-29 | 2007-12-28 | 치환된 3-페닐-1-(페닐티에닐)프로판-1-온 및 3-페닐-1-(페닐푸라닐)프로판-1-온의 유도체, 그 제조 및 용도 |
JP2009543511A JP5371776B2 (ja) | 2006-12-29 | 2007-12-28 | 置換3−フェニル−1−(フェニルチエニル)プロパン−1−オンおよび3−フェニル−1−(フェニルフラニル)プロパン−1−オンの誘導体、その調製および使用 |
EA200900900A EA017449B1 (ru) | 2006-12-29 | 2007-12-28 | Производные замещенных 3-фенил-1-(фенилтиенил)пропан-1-онов и 3-фенил-1-(фенилфуранил)пропан-1-онов, их получение и применение |
BRPI0720633A BRPI0720633B8 (pt) | 2006-12-29 | 2007-12-28 | compostos derivados de 3-fenil-1-(feniltienil)propano-1-ona e de 3-fenil-1-(fenilfuranil)propano-1-ona substituídos e composição farmacêutica |
AU2007344310A AU2007344310B2 (en) | 2006-12-29 | 2007-12-28 | Substituted 3-phenyl-1-(phenylthienyl)propan-1-one and 3-phenyl-1-(phenylfuranyl)propan-1-one derivatives, and preparation and use of same |
CA2673761A CA2673761C (fr) | 2006-12-29 | 2007-12-28 | Derives de 3-phenyl-1-(phenylthienyl)propan-1-one et de 3-phenyl-1-(phenylfuranyl)propan-1-one substitues, preparation et utilisation |
US12/448,668 US8088819B2 (en) | 2006-12-29 | 2007-12-28 | Derivatives of substituted 3-phenyl-1-(phenylthienyl)propan-1-ones and of 3-phenyl-1-(phenylfuranyl) propan-1-ones, preparation and use |
EP07872038.0A EP2079722B1 (fr) | 2006-12-29 | 2007-12-28 | Derives de 3-phenyl-1- (phenylthienyl) propan-1-one et de 3-phenyl-1- (phenylfuranyl) propan-1-one substitues, preparation et utilisation |
NZ577909A NZ577909A (en) | 2006-12-29 | 2007-12-28 | Substituted 3-phenyl-1-(phenylthienyl)propan-1-one and 3-phenyl-1-(phenylfuranyl)propan-1-one derivatives, and preparation and use of same |
IL199488A IL199488A (en) | 2006-12-29 | 2009-06-22 | Annotations of 3 - Phenyl – 1– (Phenylthanyl) Propylene – 1 – Helene and 3-Phenyl – 1– (Phenylfuranil) Propylene – 1 – Helmet |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0656067 | 2006-12-29 | ||
FR0656067A FR2910894A1 (fr) | 2006-12-29 | 2006-12-29 | Derives de 3-phenyl-1-(phenylthienyl)propan-1-one et de 3-phenyl-1-(phenylfuranyl)propan-1-one substitues, preparation et utilisation. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008087366A2 true WO2008087366A2 (fr) | 2008-07-24 |
WO2008087366A3 WO2008087366A3 (fr) | 2008-10-23 |
Family
ID=38255443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2007/052634 WO2008087366A2 (fr) | 2006-12-29 | 2007-12-28 | Derives de 3-phenyl-1-(phenylthienyl)propan-1-one et de 3-phenyl-1-(phenylfuranyl)propan-1-one substitues, preparation et utilisation |
Country Status (14)
Country | Link |
---|---|
US (1) | US8088819B2 (fr) |
EP (1) | EP2079722B1 (fr) |
JP (1) | JP5371776B2 (fr) |
KR (1) | KR101505577B1 (fr) |
CN (1) | CN101605775B (fr) |
AU (1) | AU2007344310B2 (fr) |
BR (1) | BRPI0720633B8 (fr) |
CA (1) | CA2673761C (fr) |
EA (1) | EA017449B1 (fr) |
ES (1) | ES2544959T3 (fr) |
FR (1) | FR2910894A1 (fr) |
IL (1) | IL199488A (fr) |
NZ (1) | NZ577909A (fr) |
WO (1) | WO2008087366A2 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
WO2011157827A1 (fr) | 2010-06-18 | 2011-12-22 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
WO2011161030A1 (fr) | 2010-06-21 | 2011-12-29 | Sanofi | Dérivés de méthoxyphényle à substitution hétérocyclique par un groupe oxo, leur procédé de production et leur utilisation comme modulateurs du récepteur gpr40 |
WO2012004269A1 (fr) | 2010-07-05 | 2012-01-12 | Sanofi | Dérivés d'acide ( 2 -aryloxy -acétylamino) - phényl - propionique, procédé de production et utilisation comme médicament |
WO2012004270A1 (fr) | 2010-07-05 | 2012-01-12 | Sanofi | Dérivés 1,3-propanedioxyde à substitution spirocyclique, procédé de préparation et utilisation comme médicament |
WO2012010413A1 (fr) | 2010-07-05 | 2012-01-26 | Sanofi | Acides hydroxy-phényl-hexiniques substitués par aryloxy-alkylène, procédé de production et utilisation comme médicament |
WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
WO2013045413A1 (fr) | 2011-09-27 | 2013-04-04 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
WO2022238445A1 (fr) | 2021-05-11 | 2022-11-17 | Genfit | Agonistes ppar destinés à être utilisés dans le traitement d'une insuffisance hépatique |
WO2022238448A1 (fr) | 2021-05-11 | 2022-11-17 | Genfit | Agonistes de dérivés d'elafibranor de ppar destinés à être utilisés dans le traitement de la septicémie |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2851062A1 (fr) * | 2011-10-26 | 2013-05-02 | F. Hoffmann-La Roche Ag | 1-cycloalkyl- ou 1-heterocyclyl-hydroxyimino-3-phenyl-propanes |
WO2021169769A1 (fr) * | 2020-02-28 | 2021-09-02 | 四川科伦博泰生物医药股份有限公司 | Composé aromatique et composition pharmaceutique et utilisation associées |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004063181A1 (fr) | 2003-01-03 | 2004-07-29 | Genzyme Corporation | Derives d'uree et leur utilisation comme agents anti-inflammatoires |
WO2006090920A1 (fr) | 2005-02-28 | 2006-08-31 | Nippon Chemiphar Co., Ltd. | ACTIVATEUR POUR LE RÉCEPTEUR δ ACTIVÉ PAR LES INDUCTEURS DE LA PROLIFÉRATION DE PEROXYSOMES |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0111523D0 (en) * | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
EP1583754A1 (fr) * | 2003-01-06 | 2005-10-12 | Eli Lilly And Company | Modulateurs du recepteur ppar |
EP1701938B1 (fr) * | 2004-01-08 | 2012-07-25 | Genfit | Composes derives de 1,3-diphenylprop-2-en-1-one, preparation et utilisations |
-
2006
- 2006-12-29 FR FR0656067A patent/FR2910894A1/fr active Pending
-
2007
- 2007-12-28 AU AU2007344310A patent/AU2007344310B2/en not_active Ceased
- 2007-12-28 WO PCT/FR2007/052634 patent/WO2008087366A2/fr active Application Filing
- 2007-12-28 JP JP2009543511A patent/JP5371776B2/ja not_active Expired - Fee Related
- 2007-12-28 EA EA200900900A patent/EA017449B1/ru not_active IP Right Cessation
- 2007-12-28 EP EP07872038.0A patent/EP2079722B1/fr not_active Not-in-force
- 2007-12-28 CN CN200780051301.5A patent/CN101605775B/zh not_active Expired - Fee Related
- 2007-12-28 CA CA2673761A patent/CA2673761C/fr active Active
- 2007-12-28 US US12/448,668 patent/US8088819B2/en not_active Expired - Fee Related
- 2007-12-28 NZ NZ577909A patent/NZ577909A/en not_active IP Right Cessation
- 2007-12-28 BR BRPI0720633A patent/BRPI0720633B8/pt not_active IP Right Cessation
- 2007-12-28 ES ES07872038.0T patent/ES2544959T3/es active Active
- 2007-12-28 KR KR1020097015966A patent/KR101505577B1/ko active IP Right Grant
-
2009
- 2009-06-22 IL IL199488A patent/IL199488A/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004063181A1 (fr) | 2003-01-03 | 2004-07-29 | Genzyme Corporation | Derives d'uree et leur utilisation comme agents anti-inflammatoires |
WO2006090920A1 (fr) | 2005-02-28 | 2006-08-31 | Nippon Chemiphar Co., Ltd. | ACTIVATEUR POUR LE RÉCEPTEUR δ ACTIVÉ PAR LES INDUCTEURS DE LA PROLIFÉRATION DE PEROXYSOMES |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
WO2011157827A1 (fr) | 2010-06-18 | 2011-12-22 | Sanofi | Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases |
WO2011161030A1 (fr) | 2010-06-21 | 2011-12-29 | Sanofi | Dérivés de méthoxyphényle à substitution hétérocyclique par un groupe oxo, leur procédé de production et leur utilisation comme modulateurs du récepteur gpr40 |
WO2012004269A1 (fr) | 2010-07-05 | 2012-01-12 | Sanofi | Dérivés d'acide ( 2 -aryloxy -acétylamino) - phényl - propionique, procédé de production et utilisation comme médicament |
WO2012004270A1 (fr) | 2010-07-05 | 2012-01-12 | Sanofi | Dérivés 1,3-propanedioxyde à substitution spirocyclique, procédé de préparation et utilisation comme médicament |
WO2012010413A1 (fr) | 2010-07-05 | 2012-01-26 | Sanofi | Acides hydroxy-phényl-hexiniques substitués par aryloxy-alkylène, procédé de production et utilisation comme médicament |
WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
WO2013045413A1 (fr) | 2011-09-27 | 2013-04-04 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
WO2022238445A1 (fr) | 2021-05-11 | 2022-11-17 | Genfit | Agonistes ppar destinés à être utilisés dans le traitement d'une insuffisance hépatique |
WO2022238448A1 (fr) | 2021-05-11 | 2022-11-17 | Genfit | Agonistes de dérivés d'elafibranor de ppar destinés à être utilisés dans le traitement de la septicémie |
Also Published As
Publication number | Publication date |
---|---|
WO2008087366A3 (fr) | 2008-10-23 |
KR101505577B1 (ko) | 2015-03-30 |
CN101605775A (zh) | 2009-12-16 |
AU2007344310A1 (en) | 2008-07-24 |
NZ577909A (en) | 2012-03-30 |
IL199488A (en) | 2013-10-31 |
FR2910894A1 (fr) | 2008-07-04 |
EP2079722A2 (fr) | 2009-07-22 |
BRPI0720633A2 (pt) | 2014-03-25 |
KR20090102843A (ko) | 2009-09-30 |
EA200900900A1 (ru) | 2010-02-26 |
CA2673761C (fr) | 2016-02-23 |
US8088819B2 (en) | 2012-01-03 |
CN101605775B (zh) | 2014-11-12 |
EA017449B1 (ru) | 2012-12-28 |
US20100029745A1 (en) | 2010-02-04 |
BRPI0720633B8 (pt) | 2021-05-25 |
ES2544959T3 (es) | 2015-09-07 |
CA2673761A1 (fr) | 2008-07-24 |
BRPI0720633B1 (pt) | 2019-11-26 |
AU2007344310B2 (en) | 2013-08-15 |
JP2010514745A (ja) | 2010-05-06 |
JP5371776B2 (ja) | 2013-12-18 |
EP2079722B1 (fr) | 2015-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2079722B1 (fr) | Derives de 3-phenyl-1- (phenylthienyl) propan-1-one et de 3-phenyl-1- (phenylfuranyl) propan-1-one substitues, preparation et utilisation | |
WO2008087367A2 (fr) | Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazodyl)-phenyl-propan-1-one substitues, preparations et utilisations | |
EP2046716B1 (fr) | Derives de 1,3-diphenylpropane substitues, preparations et utilisations | |
WO2008087365A2 (fr) | Derives de 1,3-diphenylpropane substitues, preparations et utilisations | |
FR2898892A1 (fr) | Derives de n-(phenethyl)benzamide substitues,preparation et utilisations | |
FR2898894A1 (fr) | Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations | |
WO2006035157A2 (fr) | Composes derives de n- (benzyl) phenylacetamide substitues , preparation et utilisations comme ligands des ppar dans le traitement des dereglements lipidiques et/ou glucidiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780051301.5 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007872038 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07872038 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 577909 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007344310 Country of ref document: AU Ref document number: 2673761 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009543511 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12448668 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4367/DELNP/2009 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2007344310 Country of ref document: AU Date of ref document: 20071228 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200900900 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097015966 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0720633 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090626 |